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5-HT3 RECEPTOR LIGANDS AND THEIR EFFECT ON PSYCHOMOTOR
STIMULANTS
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Virginia Commonwealth University, 2008
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Drug abuse and addiction are considered to be a result, at least in part, of the
rewarding effects produced by increasing dopamine levels. 5-HT3 serotonin receptors have
been shown to indirectly affect dopamine levels. Therefore, the effect of the 5-HT3
receptor partial agonist, MD-354, on the actions of psychomotor stimulants was analyzed
in mouse locomotor activity assays to determine whether MD-354 is working through a 5HT3 receptor agonist or antagonist mode of action. Studies with (+)amphetamine and
xxi

xxii
(+)methamphetamine in combination with MD-354 indicated MD-354 is either devoid of
action or is behaving similar to the 5-HT3 receptor antagonist, ondansetron. This effect
could be occurring centrally; however peripheral effects can not be discounted.

In

combination with cocaine, MD-354 behaved similar to the 5-HT3 receptor agonist, SR
57227A, known to act both centrally and peripherally. This difference between central and
peripheral effects could account for the different modes of action observed with MD-354.
Studies also involved synthesis of potentially brain-penetrant carbamate analogs of
MD-354, and QSAR to assist in validating a 5-HT3 receptor agonist pharmacophore.

I. Introduction

Drug abuse and addiction are growing problems in today’s society, where
prevention is the only real treatment. There are various drugs available, both prescription
drugs and illegal drugs, that are abused due to their positive (i.e., rewarding) effects.
Some common effects that lead to abuse include feelings of euphoria and stress relief.1
However, repetitive use, tolerance, and dependence (whether psychic or physical) lead to
abuse, addiction, and the unfortunate withdrawal that follows when an addict no longer
has access to the drug of abuse.
Some of the most commonly abused psychomotor stimulants on the market are
the Schedule II drugs amphetamine, usually in the form of prescription medications,
methamphetamine, which is more commonly found on the street in an impure form, or in
prescription medications, and cocaine, most commonly a street drug. All three drugs
have been shown to have an effect on the monoamines dopamine (involved with
cognition, memory, and reward), norepinephrine (involved with memory, mood, and
arousal), and serotonin (involved with mood, appetite, anxiety, reward, and aggression).2
DOM is a phenylalkylamine hallucinogen that produces euphoric and stimulant
effects at low doses, but more hallucinogenic effects at higher doses.3 DOM is
structurally similar to amphetamine and could possibly behave in a similar manner even
though it is not classified as a psychomotor stimulant.
1

2
The phenylalkylamine psychomotor stimulant amphetamine, and its more potent analog
methamphetamine, increase synaptic dopamine levels through several different methods:
blocking dopamine reuptake and releasing dopamine from vesicles in the presynaptic
terminal.4,5 Cocaine, a non-phenylalkylamine stimulant, works by blocking reuptake of
dopamine into the presynaptic terminal.2 The positive reinforcing effects of cocaine are
due to increased synaptic dopamine levels, known as the “dopamine hypothesis”.6 The
positive subjective effects, such as the “high” observed with stimulants could be due to
differences in levels of norepinephrine, known as the “noradrenergic hypothesis”.7
Serotonin has also been shown to play a role in the rewarding effect of
psychomotor stimulants. Although there are numerous 5-HT receptor populations and
subpopulations, the receptor population of interest when describing drugs of abuse is the
5-HT3 receptor. Of the seven 5-HT receptor families, 5-HT3 receptors are the only
serotonin receptor population that is a ligand-gated ion channel (LGIC) receptor as
opposed to the others that are G-protein coupled receptors (GPCR).8 Activation of
serotonin systems, more commonly 5-HT3 receptor systems, have been shown to
modulate dopamine release. Grant reviewed that 5-HT3 receptor agonists may indirectly
increase dopamine levels whereas 5-HT3 receptor antagonists indirectly decrease
dopamine levels.9 This could be due, in part, to the location of serotonin receptors in
different regions of the brain relative to dopamine receptors, more specifically location in
the mesolimbic dopaminergic pathway.9 Further support from Tecott et al. indicated that
GABAergic input on dopamine neurons due to the quantity and distribution of 5-HT3
receptors in the CNS could account for the indirect effects on dopamine levels.10

3
MD-354 is a unique 5-HT3 receptor partial agonist, as it can behave as either an
agonist or an antagonist, that binds at 5-HT3 receptors with relatively high affinity (Ki =
35 nM).11 When administered alone, MD-354 does not produce a locomotor stimulant
effect, or might not penetrate the BBB; the latter is a possibility due to its low Log P
value of -0.64.12,13
The effects of psychomotor stimulants can be evaluated through locomotor
activity assays. Although locomotor activity assays can analyze various parameters,
some of the more common parameters involved in locomotor stimulation include
increases in movement distance and movement time, and decreased movement episodes.
Since MD-354 is a 5-HT3 receptor partial agonist, and 5-HT3 receptors have been
shown to affect dopamine levels, MD-354 may either potentiate or antagonize the effect
of psychomotor stimulants in locomotor activity assays. However, it is possible that MD354 may have no effect on the psychomotor stimulants because it might not readily
penetrate the BBB.
The purpose of this study is to determine the effect that MD-354 might have on
the psychomotor stimulants, and to characterize this effect as working through either a 5HT3 receptor agonist or 5-HT3 receptor antagonist mode of action. Also, since MD-354
may or may not cross the BBB, more lipophilic prodrugs will be synthesized and tested in
locomotor activity assays to determine the effect. QSAR studies will be conducted on a
set of arylguanidine and arylbiguanide 5-HT3 receptor agonists and partial agonists in
order to improve Dukat’s current working 5-HT3 receptor pharmacophore model.14
Conformationally-constrained analogs will be incorporated into the model to account for

4
rotameric binding and CoMFA studies will be conducted to predict the binding affinities
of novel arylguanidine derivatives.

II. Background

A. Drug Abuse/Drug Addiction
Drug abuse has social, medical, economic, and criminal impacts costing
Americans millions of dollars per year, making treatment pertinent. The term “drug
abuse” is very vague, as its definition is based on social perceptions. Some of the more
common definitions for drug abuse entail any use of an illegal substance, use of legal
substances in excessive amounts, or even use of legal substances regardless of the
amount.1 A drug’s positive effects such as euphoric feelings, stress relief, and
improvement of performance, are key factors in why drugs readily become abused.1
Tolerance occurs when the rewarding effects are no longer achieved by the initial dose;
therefore a higher dose is necessary to achieve an earlier effect.

Drug abuse and

tolerance can lead to addiction and psychic dependence (i.e., continuous administration is
necessary to achieve a euphoric feeling, regardless of the harmful consequences).1 This is
not to be confused with physical dependence, which involves a physiological reaction,
such as withdrawal symptoms, to the absence of the drug.1 Withdrawal symptoms are
negative physical symptoms such as irritability, anxiety, fatigue, and even nausea.1 Drug
addiction and dependence are not synonymous, because not all addicts are dependent
upon the drug. 1
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The extent to which a drug has pharmacological properties that are able to predict
a drug’s likelihood of abuse and dependence is termed “abuse liability”.15 If a drug is
determined to have abuse potential, it can then be regulated under the Controlled
Substances Act (CSA) as a scheduled drug. This legislation was created in 1970, as a
reorganization of government agencies, to regulate these drugs. Schedule I drugs have a
high potential for abuse, with no accepted medical use or safety for use. Substances in
Schedule II – V have medical use, with differences in abuse potential.16 Schedule II
drugs have high abuse potential resulting in high psychological and/or physical
dependence, whereas substances in Schedules III-V have lower abuse potential, as well as
moderate to low physical or psychological dependence.16 Some countries and agencies
further divide controlled substances into a sixth schedule that can be broken into three
parts: Part 1 includes Class A precursors, Part 2 includes Class B precursors, and Part 3
contains any preparation or mixture set out in Part 1 or Part 2.17 Some examples of
Schedule VI Part 1 substances include acetic anhydride, lysergic acid, piperonal, and
potassium permanganate.17 Part 2 substances include acetone, ethyl ether, hydrochloric
acid, sulfuric acid, and toluene.17
In addition to the abuse of legal substances such as alcohol and nicotine, and the
abuse of prescription drugs, some of the most widely abused substances include opioids,
stimulants, hallucinogens, and related designer drugs.18 Even though abused drugs are
easily classified on the basis of abuse potential, they might act by different mechanisms.
By understanding the mechanisms of action of each drug, it might be easier to find
effective treatments for drug abuse and addiction and, possibly, drug abuse prevention.
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B. Classification
1. Opioids
The use and abuse of opium was reported as far back as 200 B.C.; opium is a
substance occurring naturally from poppy seeds of Papaver somniferum.19 Opioids can
be defined as opium alkaloids, their synthetic derivatives, and peptides with morphinelike pharmacological effects that are antagonized by an opioid antagonist.19 These agents
are thought to work through one or more of three major opioid receptors: mu (μ), kappa
(κ), and delta (δ), to help with postoperative analgesia, myocardial infarction, trauma,
burns, and orthopedic pain.20 Most opioids, such as morphine, the principle alkaloid of
opium, codeine, hydrocodone, and oxycodone, are Schedule II drugs that help with
moderate to severe pain, and that have abuse and addiction potential.21 Opioids are
commonly abused due to their euphoric, analgesic, and sedative effects.20 However, an
opioid overdose can lead to respiratory failure.20 Heroin, an acetylated form of morphine,
is currently a Schedule I drug that is highly addictive.21 However, once heroin is no
longer available to a heroin addict, intense withdrawal symptoms occur, such as nausea,
vomiting, diarrhea, anxiety, and depression.20 Currently there are two drug replacement
therapies for heroin addicts: methadone and buprenorphine.20,22
With most other drugs of abuse, prevention is the only treatment for addiction, as
no other medications are available. Because “replacement therapy” is available here, and
because replacement therapy might be possible for other types of drug abuse, drug
replacement therapy and drug abuse treatment are a major area of interest to help treat
drug addiction.
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2. Stimulants
a) Analeptics
Psychostimulants are drugs that have a direct neurological effect such as
increased alertness and energy, appetite suppression, and euphoria.23 There are two main
categories of stimulants: analeptics and behavioral stimulants. Analeptic stimulants are
not as readily abused as behavioral stimulants; analeptics work primarily on autonomic
centers generally affecting respiration and circulation.18 Some examples of analeptics
include strychnine and caffeine. Strychnine is considered an analeptic stimulant because
it increases respiration and blood pressure, but is a convulsant that can be lethal at high
doses.24 Sometimes, “street drugs” such as cocaine and (+)lysergic acid diethylamide
(LSD) are “laced” with small amounts of strychnine for respiratory stimulation.24
Caffeine, a xanthine, is considered the most widely used psychoactive drug in the world
because it reduces drowsiness and fatigue while increasing heart rate and blood pressure.1
It is found in tea from Thea sinensis (and other species), and in coffee from Coffea
Arabica (and other species).25 Interestingly, although craving is observed regardless of
its lack of euphoric effects upon withdrawal of the caffeinated beverage, caffeine is not
considered addicting.1
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b) Behavioral Stimulants
i. Non-Phenylalkylamines
Behavioral stimulants have more of a central stimulatory effect than analeptics,
resulting in changes in motor activity. The class of behavioral stimulants can further be
divided into non-phenylalkylamine and phenylalkylamine (PAA) stimulants. The most
common non-phenylalkylamine stimulant is cocaine, a psychotropic drug used for the
past 2000 years with 25.6% of 26-34 year olds using cocaine at least once in their
lifetime;26 about five million people, just in the United States, use cocaine each year.27
Cocaine, a naturally occurring drug, is found as a constituent of the Erythoxylon coca
species of plants in South America.18 In the 1860’s, cocaine was used in several different
tonics, which gave them “magic properties”.26 It was even found as the main stimulant in
Coca Cola.18 In the late 1800’s cocaine served medical purposes such as treatment for
morphine addiction and as a topical anesthetic in ophthalmology.26 Due to its stimulant
properties, as well as the fact that it alleviated hunger, and allowed people to forget
reality, it became a highly abused drug, eventually labeled as a Schedule II substance.26
Cocaine has many different street names, such as “blow”, “crack”, “rock”, and “coke”,
along with different forms: hydrochloride salt and free base.

Cocaine, a positive

reinforcer, has a high abuse potential due to its rapid onset of action with “rush” central
stimulatory effects including intense euphoria, psychic energy, heightened sexual
excitement, and increased self-confidence.26,28,29 However, cocaine abusers can also
experience paranoia, hallucinations, and dysphoria, during their subsequent “crash”, with
toxic concentrations potentially leading to fatal cardiac arrhythmias.26
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Cocaine works through dopamine (DA), norepinephrine (NE), and serotonin (5HT) mechanisms, with its stimulant effect mainly a result of the dopaminergic
mechanism. Dopamine nerve terminals contain a dopamine transporter (DAT), located
perisynaptically, which terminates the actions of dopamine by a transport mechanism.2
Cocaine works by blocking the DAT, preventing reuptake of dopamine into the
presynaptic nerve terminal.2 This increases extracellular dopamine levels, producing a
heightened state of euphoria.2 It is important to note that although cocaine blocks the
dopamine transporter, it itself is not transported into the nerve terminal.2
Cocaine’s reinforcing effects are due to its ability to bind to the dopamine
transporter and block reuptake of dopamine into the presynaptic terminal.6 The better
able an agent to bind to the dopamine transporter, the greater the blockade, allowing more
dopamine in the synapse, which accounts for the euphoric effect. Structure-activity
studies show that there are some key aspects to the structure of cocaine that can enhance
or decrease its activity. By simply switching the configuration of cocaine from R to S, by
switching the carbomethoxy group from the C-2 position to the C-4 position, the activity
of cocaine decreases more than 100-fold (1; Figure 1).30

The presence of the

carbomethoxy group at the 2-position is optimal for cocaine-like activity.30 Removal of
this group or replacement with most other substituents decreases activity, with one
exception; different ester groups can replace the carbomethoxy substituent with only
small alterations in activity.30 Also, at this position stereochemistry is important:
epimerization from β to α substantially decreases activity.30 Similar decreases in activity
are observed with the same epimerization at the C-3 position.30 Changes at the nitrogen
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position can have varying effects. For example, changing the length of the substituent
chain has little to no effect on activity, whereas changing the functional group such as
from an amine to an amide or even conversion from a tertiary amine to a quaternary
amine significantly reduces activity.30 Interestingly, it was observed that the nitrogen
atom can be moved from the 8-position to the 6- or 7-position without decreasing binding
affinity to the dopamine transporter.30 These, as well as other, structural changes allow
for a better understanding of the binding profile of cocaine.

CH3
N

CO2CH3

8
1

2

7
5
6

4

3

O
O

Cocaine (1)

Figure 1. Structure of cocaine (1) labeled for discussion of structure-activity relationship
studies.
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ii. Phenylalkylamines
Several different drugs make up the stimulant class of phenylalkylamines: agents
that contain a phenyl group, an alkyl chain, and an amine.18 The most widely recognized
stimulant is amphetamine (2; Figure 2), a central stimulant, anorectic, and
sympathomimetic agent.18 Sympathomimetic drugs are drugs that mimic the actions of
endogenous neurotransmitters stimulating the sympathetic nervous system.24

Of the

stimulant phenylalkylamines, amphetamine is considered the prototypical drug, with
others referred to as “amphetamine-like” or “amphetaminergic”.18 Unlike many drugs of
abuse, amphetamine is not naturally occurring. It was first synthesized in 187724 as an
optical isomer; (+)amphetamine is the more potent of the two isomers.31

In 1930,

amphetamine began to be used therapeutically in the treatment of narcolepsy and
depression.24 However, its positive effects of mood elevation, euphoria, alleviation of
fatigue, and improving task performance, resulted in abuse.24 Finally, in 1970 the Drug
Enforcement Administration (DEA) labeled amphetamine as a Schedule II drug.21
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Figure 2. Structures of amphetamine and some important derivatives.
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Currently, amphetamines, such as Dexedrine , Ferndex , and Oxydess II® are
®

®

used to treat narcolepsy, attention deficit hyperactivity disorder (ADHD), and obesity.24
Both with prescribed and illicit amphetamines, toxic levels can create “amphetamine
psychosis”, aggression, delusions, arrhythmias, and convulsions.32 “Amphetamine
psychosis” is a paranoid-hallucinatory psychosis in a setting of clear consciousness in
which formal aspects of thought are relatively intact, but in which delusions evoke
intense fear.32 Sometimes, patients with amphetamine psychosis are misdiagnosed as
having schizophrenia, a disease for which the symptoms are indistinguishable.23
Amphetamine withdrawal can result in a

dysphoric state resulting in anhedonia,

depression, anxiety, and social inhibition.33,34 Therefore, some attempts have been made
to treat amphetamine addicts with antidepressants such as mirtazapine, fluoxetine, and
imipramine.35,36 Amphetamine abuse poses a severe problem as there currently is no
effective treatment on the market for addicts, whose withdrawal symptoms could be
detrimental.
Methamphetamine (3; Figure 2), a derivative of amphetamine with a methylated
amine, is a more popular street drug than amphetamine, as it generally has the same type
of effects as amphetamine, but with a higher potency.18 Methamphetamine’s popularity
is due to its ease of synthesis, with over 50% of clandestine labs seized in 1981 being
“meth” labs.24 Methamphetamine synthesis is so easy it can be made in the trunk of a car
using the “special ingredients” and two-liter bottles.37 Methamphetamine can be
synthesized by numerous routes, the most common using (-)-ephedrine or (+)pseudoephedrine, ingredients in over-the-counter decongestants and bronchodilators.24
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For this reason, over-the-counter medications with these ingredients have recently been
under strict control. The therapeutic forms of methamphetamine are Desoxyn®, Adipex®,
and Methedrine® which are used for ADHD and obesity.2,24 However, street versions of
methamphetamine include “meth”, “speed”, “crank”, “go”, “crystal”, and “ice”, all of
which are hydrochloride salts for greater bioavailability.24 Methamphetamine is a
Schedule II drug.21 Like amphetamine, methamphetamine use causes euphoria, increased
alertness, self-confidence, and suppresses fatigue.38 However, withdrawal from
methamphetamine use also causes a depressive state, with 49.4% of arrested “meth”
addicts stating they had thoughts of suicide.39 As with amphetamine, treatment for
methamphetamine addicts is also elusive.
Stimulatory effects of phenylalkylamines mainly result from their effect on
dopamine levels, primarily D1 receptors.40

Amphetamine, and amphetamine-like

phenylalkylamines that have a stimulant effect, such as methamphetamine, work by
increasing the release of dopamine by affecting vesicular monoamine transporter-2
(VMAT-2), preventing reuptake of dopamine into presynaptic terminals, and affecting
monoamine oxidase isozymes MAO-A and MAO-B.4,5 This increase of dopamine levels
causes central stimulant actions.

Also, the activity of dopamine receptors can be

modulated by NE and 5-HT.40 Some of the non-stimulant phenylalkylamines do not
readily effect dopamine, but have a greater effect on 5-HT levels.41 The different effects
of phenylalkylamine stimulants on DA, NE, and 5-HT can be largely attributed to minor
structural changes.
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It is observed that small modifications to the structure of amphetamine, the
prototypical phenylalkylamine stimulant, can cause vast changes in the activity, potency,
effects, and even mechanism of action, of the drug. When analyzing structure-activity
relationships of phenylalkylamine stimulants, there are five key points to be considered:
terminal amine, chiral center, α-methyl group, β-position, and aromatic substitution.
With the amine group, it is observed that primary amines are more potent than secondary
amines (with the exception of methamphetamine), which are more potent than tertiary
amines.18 Length of the amine substituent has an effect on secondary amines, with a
decrease in activity as the length of the substituent is increased.18 There is a limit of bulk
tolerance as larger substituents usually result in agents having little to no stimulant
character.18
The α–methyl group seems pertinent for effect as demethylation to
phenylethylamine results in loss of stimulant activity.18 Also, homologation to larger,
bulkier substituents decreases stimulant effect.18 The presence of an α-methyl group
creates a chiral center; the S(+) isomer is more potent than the R(-) isomer.18 Changes at
the β-position have varying effects. Hydroxylation of the β-carbon to norephedrine and
norpseudoephedrine decreases stimulant actions.18 Ephedrine and pseudoephedrine (4;
Figure 2) are β-oxidized analogs of methamphetamine.18

The abuse potential of

ephedrine and pseudoephedrine is low but dependence can occur.25 Some side effects of
these drugs include anxiety, headache, tachyarrhythmia, and hypertensive crisis.25
However, oxidation of norephedrine to cathinone results in an agent that retains
equal to or greater potency as compared to amphetamine.18,42 Cathinone (5; Figure 2) is
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a constituent of Catha edulis, the “Khat” shrub which is predominantly found in East
Africa.25 Its stimulant effects are similar to that of amphetamine, including euphoria,
excessive talkativeness, focus, excitement, elimination of hunger, and insomnia, with a
high chance of tolerance occurring.41,43 The toxic effects of cathinone are limited, but
include aggressive behavior, hallucinatory psychosis, and fatal hyperthermina.25 The Nmonomethyl analog of cathinone, methcathinone (6; Figure 2), a name originally coined
in the Glennon laboratories,44 is a designer drug synthesized from ephedrine, linking it to
its common name ephedrone.25 S(-)Methcathinone, which is found more often in the
clandestine market than the R(+)-isomer or the racemic mixture is referred to as “CAT”.45
As cathinone’s effects are similar to those of amphetamine, methcathinone is equally
similar to methamphetamine.25
Lastly is manipulation of the ring by adding substituents. For the most part,
adding substituents to the ring decreases and may even abolish amphetamine-like
stimulant action as seen with p-chloroamphetamine (PCA) and fenfluramine (7 and 8,
respectively; Figure 2).18 PCA depletes serotonin levels in the brain, and produces a
neurotoxic effect.46 Instead of the euphoric effect caused by amphetaminergic agents,
PCA causes aggression, anxiety, and panic disorders.46 (±)Fenfluramine, marketed as
Pondimin®, and its more potent stereoisomer (+)fenfluramine (Redux®), are nonamphetaminergic phenylalkylamine derivatives once used clinically for appetite
suppression.41 However, due to the side effects of cardiovalvulopathy, as well as primary
pulmonary hypertension, these two drugs were withdrawn from the market in 1997.41
Like PCA, fenfluramine also depletes serotonin levels in the brain.46 However, this
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decrease is selective and may account for the development of tolerance to fenfluramine.
Some, negative effects of fenfluramine include depression and aggravated psychosis.46
One of the key designer drugs on the market is N-methyl-1-(3,4methylenedioxyphenyl)-2-aminopropane, more commonly referred to as MDMA.18
MDMA (9; Figure 2) was first synthesized in 1914 as an appetite suppressant and for
psychotherapy to facilitate communication, but never had legal therapeutic use.24,25
MDMA is an empathogen, in so much as it increases sociability, empathy, and feelings of
well being.24 Also, there are readily observed physical reactions, such as trismus (jaw
clenching) and bruxism (teeth grinding), which account for “ravers” usually chewing
gum or sucking on a pacifier.47 Overdoses can cause panic, paranoia, psychosis and
delirium with toxic (fatal) effects including convulsions, hyperthermia, behavioral
changes, and acute renal failure.24 There are several street names for MDMA, including
“Ecstasy”, “XTC”, “M&M”, “Zen”, and “Adam”.18,24 Its lack of therapeutic use resulted
in its placement in Schedule I.21

The demethylated form of MDMA is 1-(3,4-

methylenedioxyphenyl)-2-aminopropane (MDA), which has both hallucinogenic and
stimulant character based on optical isomers.18
phenylalkylamines result in hallucinogenic agents.

Other structural changes of the
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3. Non-stimulant Phenylalkylamines
Hallucinogens, upon administration of a single effective dose, consistently
produce changes in thought, mood, and perception with little memory impairment,
produce little stupor, narcosis, or excessive stimulation, produce minimal autonomic side
effects, and are non-addicting.48 The classical hallucinogens are hallucinogens that bind
at 5-HT2 serotonin receptors (5-HT2 hypothesis of hallucinogen action)18 and are
recognized by animals trained to discriminate 1-(2,5-dimethoxy-4-methylphenyl)-2aminopropane (DOM) (10; Figure 3) from vehicle.31,49 The family of 5-HT2 receptors
can be further divided into 5-HT2A, 5-HT2B, and 5-HT2C receptors with evidence that 5HT2A receptors play the major role in the hallucinogenic action.50 The classical
hallucinogens can further be divided into several other classes: lysergic acid derivatives
(e.g. LSD), phenylethylamines (e.g. mescaline), indolealkylamines (e.g. DMT), and other
indolic derivatives (β-carbolines).18
phenylalkylamines,

which

The main focus of the present study is on

includes

both

phenylisopropylamines

and

phenylethylamines.18
Mescaline (11; Figure 3), one of the most commonly known phenylethylamines,
is naturally occurring from cactus, usually peyote (Lophophora williamsii).51 Onset of
action usually has some negative effects such as nausea, vomiting, and diarrhea, but once
subsided, visual hallucinations and perceptual distortions occur.51 Some side effects
include emotional instability and anxiety, with toxic effects of bradycardia, hypotension,
and respiratory depression: death is a rare result of toxicity.51 There is no therapeutic use
for mescaline, it is currently classified as a Schedule I drug.18
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Figure 3. Structures of common phenylalkylamine hallucinogens.

DOM (10; Figure 3), 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane is a
phenylisopropylamine used as the prototypical hallucinogen in drug discrimination
studies.18 The R(-)-isomer of DOM is more potent than the S(+)-isomer or the racemic
mixture.52 At low doses, DOM increases self-awareness, while producing feelings of
anxiety, euphoria, and dysphoria, without producing a hallucinogenic effect.3 However,
at higher doses, DOM produces hallucinogenic effect similar to LSD and mescaline;3
DOM is >80 times more potent than mescaline.53 One of the original street names for
DOM was “STP”.3 DOM has proven to be more hazardous than LSD, as it has a longer
onset of action. Therefore, impatient people could take multiple doses of DOM causing
an overdose and even hospitalization.54 DOM is believed to work as an agonist at central
serotonin (5-HT) sites,55 more specifically through a 5-HT2 mechanism.56,57
Structural changes to DOM, the prototypical hallucinogen, cause changes in
potency and activity. With respect to the terminal amine of DOM, a primary amine is
more potent than a secondary amine, and homologation of the α-methyl group decreases
potency.18 However, opposite effects are observed at the chiral center as well as with
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aromatic substitution, when compared with amphetamine.
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Effect of substitution at the

β-position is highly dependent upon configuration. Addition of a β-hydroxy group in the
R-configuration has little effect on affinity versus DOB, however the same addition in the
S-configuration decreases affinity by 50-fold from R(-)DOB.58 Also, addition of a βmethoxy group has a 100-fold decrease in affinity in the S-configuration but maintains
affinity in the R-configuration.58 Increasing the length of the 4-methyl group enhances
potency.18 However, if this lengthening surpasses n-propyl then potency decreases.18
Activity is maintained with substitution at the 4-position with electron-withdrawing
groups such as bromine or iodine (i.e., DOB or DOI respectively).18 The R(-)isomer has
been shown to be more active than the S(+)isomer which in some cases has zero
activity.18

Also, reduction in activity and potency can be observed through N-

monomethylation.18 This comparison between amphetamine and DOM is summarized in
Table 1.
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Table 1. Comparative structure-activity relationships of amphetamine-like stimulants vs.
DOM-like hallucinogens.18
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The behavioral actions of arylalkylamines, in this case phenylalkylamines, can
fall into one of three categories: classical hallucinogen (H), central stimulant (S), and
PMMA-like (P) (Figure 4).18,59,60 Each category contains a prototypical drug used to
characterize other drugs in drug discrimination studies: DOM represents the
hallucinogens, (+)amphetamine represents the stimulants, and PMMA, N-methyl-1-(4methoxyphenyl)-2-aminopropane,

represents

PMMA-like

actions.18,59,60

Most

phenylalkylamine drugs of abuse fall into one of these three categories, or behave similar
to more than one category. For example, MDMA would fall under intersect 2 as it
produces both amphetamine-like and PMMA-like activity.18,59,60 R(-)MDA has both
hallucinogenic-like activity as well as PMMA-like activity, placing it in intersect 3.
However the (±)MDA, produces amphetaminergic, hallucinogenic, and PMMA-like
activity, placing it in the center.18,59,60

It is important to note that through this

classification, there should be three different mechanisms of action as well as three
separate structure-activity relationships.

H
1

3
P

S
2

Figure 4. A modified Venn diagram of behavioral effects of arylalkylamines.59,60
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C. Mechanism of Action of Stimulants
The behavioral pharmacology and addictive properties of the stimulants cocaine,
amphetamine, and methamphetamine are related to the monoamines, serotonin,
norepinephrine, and dopamine. Serotonin is involved with mood, fear, sleep, appetite,
anxiety, reward, and aggression.2 Serotonin is produced in the raphe nuclei of the
brainstem and moves to the cortex, thalamus, basal ganglia, hippocampus, and
amygdala.2 Norepinephrine is involved with arousal, attention, memory, and mood, and is
produced in the locus coeruleus.2 It is also found in the hypothalamus, cortex,
hippocampus, and striatal regions, along with several other parts of the brain.2 Dopamine
is involved in many processes such as movement, cognition, memory, and reward,61 and
plays a primary role in the reinforcing effects of cocaine, known as the dopamine
hypothesis. Dopamine makes up approximately 80% of the catecholamine content in the
brain.62 All three of these neurons express transporter proteins that belong to the Na+/Clsuperfamily, (norepinephrine transporter, NET; dopamine transporter, DAT; and 5-HT
transporter, SERT) which function to regulate monoaminergic activity in the brain.63,64
Interestingly, psychostimulants affect all three transporters; cocaine binds with almost
equal

affinity

to

all

three

transporters,

whereas

(+)amphetamine

and

(+)methamphetamine bind with substantially higher affinity to DAT and NET than SERT
as seen in Table 2.2 However, addictive properties of psychostimulants are due to their
effect on dopamine.2
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Table 2. Stimulant drug affinities (Ki) at monoamine transporters (cocaine affinities at
DAT and SERT are expressed as IC50 values).2
Drug

DAT

NET

(-)Cocaine

478 nM65

779 nM7

34 nM7

39 nM7

3830 nM7

114 nM66

48 nM66

2137 nM66

(+)Amphetamine
(+)Methamphetamine

SERT
304 nM65

Sometimes synonymous with addiction is withdrawal symptoms when the drug of
abuse is no longer administered. Rothman et al. proposed a dual deficit model of
stimulant addiction, stating withdrawal symptoms are a result of drug-induced dopamine
and serotonin dysfunction as seen in Figure 5.67 Dysfunction occurs when withdrawal
from chronic stimulant use leads to a decrease in availability of dopamine and
serotonin.67 Dopamine deficit consists of decreased synaptic dopamine, altered dopamine
transporter function, and/or postsynaptic receptor changes resulting in anhedonia and
psychomotor retardation.67 Serotonin deficit consists of decreased synaptic serotonin,
decreased serotonin cell activity, and/or decreased synaptic dopamine, which results in
depressed mood, obsessive compulsive thoughts and behaviors, and lack of impulse
control.67 Therefore, drugs that release dopamine or serotonin should effectively treat the
withdrawal symptoms observed with addiction (i.e., such as d-amphetamine, a dopamine
releasing agent, in the treatment of withdrawal symptoms from cocaine abuse).67
Rothman et al. also stated that a drug that acts as both a dopamine and serotonin releasing
agent could treat addiction with limited abuse liablility.67
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Dopamine Deficit

Parkinson-like
symptoms
-slow reaction time
-anergia
Anhedonia
-“pleasure center”
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Serotonin Deficit

Depression
and
Craving

OCD-like symptoms
-obsessive thoughts
-compulsive behaviors
Impulsivity
-suicide/aggression
-susceptibility to “cue
triggers”

Figure 5. Dual-deficit model of psychostimulant addiction.67

1. Dopamine
Dopamine (12; Figure 6) is a catecholamine neurotransmitter found both in the
central and peripheral nervous system, that activates dopamine G-protein coupled
receptors (GPCR).2 In the peripheral nervous system it modulates cardiovascular and
renal function, gastrointestinal motility, and the endocrine system.68

In the central

nervous system, dopamine effects cognition, emotion, locomotor activity, hunger, and
regulation of the endocrine system.68 Dopamine is produced in the substantia nigra (SN),
the ventral tegmental area (VTA), and the hypothalamus.2
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Figure 6. The structures of three important monoamine neurotransmitters.

The dopamine synapse consists both of presynaptic and postsynaptic nerve
terminals. In the presynaptic terminal, dopamine is packaged into vesicles by VMAT-2
for storage, release, and protection from oxidation and reactive consequences.69 When
DA is released into the synapse it can bind to postsynaptic dopamine receptors D1, D2,
D3, D4, and D5.68 Dopamine receptors can be divided into two groups containing the five
different dopamine receptor subtypes. The D1-like group consists of D1 and D5 receptors
and is associated with stimulatory function and located postsynaptically, whereas the D2like group is located both pre- and postsynaptically, is associated with inhibitory
function, and includes D2, D3, and D4 receptor subtypes.68,70,71

Agonists and/or

antagonists can bind selectively to D1-like receptors over D2-like receptors and with
selectivity within the D2-like group.68 However, currently no compounds can selectively
differentiate between D1 and D5 receptors.68
The structure of the dopamine receptors varies slightly between each subtype, as
some contain more amino acids than others.68 However all have a few of the same key
elements. For example, there is an NH2-terminal stretch containing various numbers of
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N-glycosylation sites between subtypes that stretches between seven transmembrane
domains and ends with the carboxy terminus.68 The carboxy terminus varies in length,
but all contain serine, threonine, and a cysteine residue.68,71 Two cysteine residues are
present in the second and third extracellular loop which creates a disulfide bridge,
providing structure stability.71 As mentioned before, D1-like receptors are involved with
stimulatory function, due to their short third intracellular loop that interacts with Gstimulatory (Gs) proteins to stimulate cAMP production.68,71 D2-Like receptors are just
opposite as their longer third intracellular loop interacts with G-inhibitory (Gi) proteins,
to inhibit cAMP production.68,71
Activation of G-proteins affects adenylyl cyclase (AC) activity, which in turn
affects cAMP accumulation modulating protein kinase A by phosphorylation or
dephosphorylation (Figure 7).62

Protein kinase A is responsible for regulating the

synthesis of cytoplasmic and nuclear proteins, the function of membrane channels, and
sensitization or desensitization of different G-protein coupled receptors.62 Dopamine
receptors are also involved with modulating the activity of phospholipase C, the release
of arachidonic acid, the activity of calcium and potassium channels, the activity of Na/H
exchangers, and Na-K ATPase.68
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Figure 7. Activation of G-protein coupled receptors by a drug causes the dissociation of
the αβγ complex. The α/GTP complex then activates second messenger systems such as
cAMP or PLC.72

The euphoric feeling resulting from stimulant use is due to an increase in
dopamine levels that can occur through several different routes.73 The DAT and VMAT2 regulate dopamine in both the synapse and cytosol; psychostimulants alter the function
of both of these types of transporters.73 Cocaine works primarily by blocking reuptake of
dopamine into the presynaptic terminal by blocking the DAT (Figure 8).30 Amphetamine
and methamphetamine both can block the reuptake of dopamine, like cocaine, but also
can cross the plasma membrane by lipophilic diffusion and act directly on vesicular

30
Also, both

63,74

monoamine carriers by releasing transmitters from the vesicle.

amphetamine and methamphetamine promote efflux of transmitter (e.g. DA) by a
transporter-mediated exchange.63

Storage Vesicles

Dopamine

Synapse

Dopamine
Transporter
A

Postsynaptic
Receptor

Figure 8. Schematic representation of a dopaminergic nerve terminal. Cocaine prevents
reuptake (“A”), whereas amphetamine and methamphetamine cause release of dopamine
from intracellular vesicles.2,18
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2. Norepinephrine
Since repeated data support that dopamine plays a role in the reward/
reinforcement behavior observed in animal models,7 the next question was to determine
the effect of norepinephrine (13; Figure 6). Both amphetamine and methamphetamine
increase NE concentrations by stimulation of release,75 whereas cocaine increases NE by
blocking reuptake.76

However, blocking reuptake may not increase extracellular

neurotransmitters as much as substrate-releasing agents, since it is nerve impulsedependent.7,77 Evidence shows that the release of NE may contribute to the positive
subjective effects, such as the “high” produced by stimulants, coined the “noradrenergic
hypothesis”.7 Since cocaine is unable to increase NE levels as much as substrate releasers
like amphetamine, the subjective effects cannot be accounted for with this type of
stimulant.7

3. Serotonin
As already discussed, central stimulants can increase synaptic levels of serotonin
(e.g. see Table 2). This increase in serotonin levels can activate various populations of 5HT receptors. The 5-HT receptor family will be described in the next section. Because
emphasis of the present work is on 5-HT3 receptors (and their ligands), these receptors
will be discussed in detail.
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D. Serotonin Receptors
1. Classification
Serotonin (5-HT) (14; Figure 6), is a neurotransmitter involved in anxiety,
aggression, depression, schizophrenia, appetite control, drug abuse, and hallucinogenic
activity.78 Currently, there are seven families of serotonin receptors, 5-HT1-5-HT7, some
of which are divided into subpopulations.78 These families are characterized based on
three components: drug binding characteristics, receptor-effector coupling, and structural
sequences for the nucleotides and amino acids.79 The majority of 5-HT receptors have
been cloned as either human, mouse, rat, or guinea pig receptors leading to the
generalization of their amino acid sequence homology.78
All of the serotonin receptors are G protein-coupled receptors except for 5-HT3
receptors which are ligand-gated ion channel (LGIC) receptors.78 G Protein-coupled
receptors consist of seven transmembrane (TM) spanning helices, with an extracellular
N-terminus, an intracellular C-terminus, and loops connecting the helices;72 the
intracellular loop between TM5 and TM6 is rather large and thought to be involved with
second messenger system coupling.78 Serotonin receptors can be coupled to two types of
second messenger systems: adenylyl cyclase (AC), where coupling can occur positively
or negatively, or phospholipase C.78

All of the different subpopulations, with the

currently accepted nomenclature, and their second messenger systems are summarized in
Table 3.
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Table 3. Classification of current populations of serotonin receptors.
Currently Accepted Name
5-HT1

5-HT2

5-HT3
5-HT4
5-HT5
5-HT6
5-HT7

Second Messenger System

5-HT1A
5-HT1B
h5-HT1D
h5-HT1B
5-HT1E
5-ht1F

AC(-)
AC(-)
AC(-)
AC(-)
AC(-)
AC(-)

5-HT2A
5-HT2B
5-HT2C

PI
PI
PI
Ion Channel
AC(+)

5-ht5A
5-ht5A

?
?
AC(+)
AC(+)

2. 5-HT3 Receptors
a) Structure and Distribution
5-HT3 receptors, formerly known as “M” receptors, due to inhibition of their
response to morphine, are in the Cys-loop family of ligand–gated ion channel receptors,
along with nicotinic acetylcholine (nACh) receptors, γ-aminobutyric acid type A
(GABAA) receptors, and glycine receptors.8,80 LGIC receptors, of the 5-HT3-type, consist
of five homopentameric subunits, each made of four transmembrane-spanning amino acid
chains (M1-M4), which form a pore; the M2 chain faces the pore.78 This pore rapidly
opens when neurotransmitter binds to the receptor,

and is permeable to sodium,

81

potassium, and calcium cations.
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M1 through M4 are connected by extracellular and

intracellular loops, with both a carboxy and amino terminus, as seen in Figure 9.78 Ion
selectivity and gating of the receptor is controlled by residues found between M1 and M3
(i.e., M2).8
Homology-based models of the extracellular domain were previously based on the
crystal structure of acetylcholine-binding protein (AChBP), however recent discoveries
have identified the crystal structure of the extracellular domain of the mouse nicotinic
acetylcholine receptor (nAChR) α1 subunit.8,82-85 These receptors are found both in the
peripheral and central nervous system. There currently are five different subtypes of 5HT3 receptors; A, B, C, D, and E, but 5-HT3A and 5-HT3B are the only two shown to form
functional receptors.86

NH3+
COO-

A

M1

M2

M3

M4

B

Figure 9. (A) Pore formed from five subunits, with M2 (shaded) facing the pore. (B)
Four transmembrane-spanning amino acid chains.78
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5-HT3 receptors are found in both the peripheral nervous system, on the terminals
of sympathetic, parasympathetic, and sensory neurons, and in the central nervous
system.9 In the central nervous system serotonin is produced in the raphe nuclei in the
brainstem and then is able to project into the cortex, thalamus, basal ganglia,
hippocampus, and amygdala.87 Evidence suggests that 5-HT3 receptors are presynaptic
excitatory receptors allowing it to regulate the release of acetylcholine, dopamine,
noradrenaline, cholecystokinin and serotonin.9 Some studies have shown that 5-HT3
receptor antagonists attenuate cocaine and amphetamine induced locomotor effects,
suggesting that 5-HT3 receptors modulate mesolimbic dopamine activity.9

This

modulation however is indirectly related to the increases in mesolimbic dopamine
induced from psychomotor stimulants alone.9 These effects are only observed with
locomotor activity, and cannot be replicated with drug discrimination or selfadministration studies, providing little information about abuse liability.88-91 Evidence,
however, does suggest that deficits in dopamine and serotonin neuronal function are
observed with stimulant abuse withdrawal.92 Since studies show there’s an indirect
correlation between 5-HT3 receptor antagonists and mesolimbic dopamine activity, as
well as evidence supporting that increased serotonin levels decrease withdrawal
symptoms, stimulants could be working, at least in part, through a 5-HT3 receptor
mechanism.9
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b) Function
5-HT3 receptors themselves, as well as 5-HT3 receptor antagonists, have a wide
array of functions. Activation of 5-HT3 receptors increases intracellular Ca2+, modulates
neurotransmitter release (dopamine and norepinephrine), excites central and peripheral
neurons, and mediates emetic and inflammatory responses.86,93 More specifically, the
receptors are involved in dopamine and acetylcholine release, as well as control of the
GABA-ergic system.80,94 This ability to indirectly regulate dopamine is why 5-HT3
receptors might be involved with drug dependence.9 Not much is known about the
function of 5-HT3 receptor agonists, although emesis may be an occurring side effect, or
partial agonists, which seem to portray an anxiolytic profile.95 However, antagonists
have been shown to relieve several types of ailments. Some 5-HT3 receptor antagonists
treat chemotherapy-induced or radiation-induced vomiting, and migraines.96,97 Some are
used in the treatment of anxiety, depression, pain, and dementia. Some 5-HT3 receptor
antagonists may suppress withdrawal symptoms in alcoholics, as well as nicotine-,
cocaine-, and amphetamine-addicts.94,96 Moreover, some are able to block the abuserelated effects of drugs.9

c) Antagonists
Hundreds of different 5-HT3 receptor antagonists have been discovered since the
initial selective 5-HT3 receptor antagonist bemesetron (15; MDL 72222) was reported.78
Bemesetron was formed by a slight structural modification to cocaine (a 5-HT-M
receptor antagonist), by the removal of a carbomethoxy group, and addition of two

78

chlorine atoms.
imidazoles.
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Current antagonists fall into two groups, keto compounds and

Some of the more common keto compounds include granisetron (16),

tropisetron (17), and zacopride (18), as seen in Figure 10.78 The imidazole-containing
compounds (Figure 11) include ondansetron (19), alosetron (20), fabesetron (21), and
ramosetron (22).78 Granisetron (16), ondansetron (19), and tropisetron (17) are of special
interest as they are highly selective and potent 5-HT3 receptor antagonists used in the
treatment of emesis associated with anticancer chemotherapy.98 Several pharmacophore
models have been reported for 5-HT3 receptor antagonists.99-104
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Figure 10. Keto-group-containing 5-HT3 receptor antagonists.78
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Figure 11. Imidazole-containing 5-HT3 receptor antagonists.78

d) Agonists
Currently, there are not many known 5-HT3 receptor agonists/partial agonists,
however the few that exist fall into one of five categories: tryptamines, arylpiperazines,
arylbiguanides, arylguanidines, and miscellaneous agents.14 There is renewed interest in
arylpiperazines which generally were initially considered non-selective for 5-HT3
receptors, or could behave as 5-HT3 receptor agonists, partial agonists, or antagonists.78
Quipazaine (23; Figure 12) binds both at 5-HT3 and 5-HT2A receptors with a Ki value of
around 1 nM.105 However, it acts as an agonist in some assays and as an antagonist in
others. Structure-activity studies have shown that appropriate structural modifications
can result in more selective 5-HT3 receptor agonists.

For example, piperazine N4-
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methylation, creating N-methylquipazine (NMQ) (24; Figure 12) enhances the selectivity
of the compound for 5-HT3 receptors.106 Also, ring-fusion creates the partial agonist MR
18445 (25; Figure 12).78

N

NH
N

N

Quipazine (23)
Figure 12.

F

CH3

N

N
N

N

NMQ (24)

H3CO

N

N

MR 18445 (25)

A few examples of arylpiperazine 5-HT3 receptor agonists and partial

agonists.

Serotonin itself is a nonselective 5-HT3 receptor agonist that does not bind with
high affinity (Ki= ca 500-1,000 nM).107 By methylating this structure to obtain 2-methyl5-HT (26; Figure 13), a partial agonist, selectivity increases while binding affinity
remains unchanged.107 However, Glennon et al. showed that 2-methyl 5-HT (26) also
binds to 5-HT6 receptors with high affinity.108 Structure-affinity studies identified a
limited region of bulk tolerance at the terminal amine of serotonin for agonism at 5-HT3
receptors. Subsequently, studies by our laboratory showed, using brain 5-HT3 receptors,
that N,N-dimethylated structure bufotenine (Ki= 280 nM) and the N,N,N-trimethylated
structure 5-HTQ (27; Figure 13) (Ki= 75 nM), bind with higher affinity and selectivity
than serotonin.109 However, the quarternary structure of 5-HTQ (27) may prevent it from
crossing the blood-brain barrier (BBB).109 Previous structure-activity studies had shown
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that di- and tri-methylation of serotonin resulted in potent serotonin agonists in a superior
cervical ganglionic cell preparation.110

Another potent and specific 5-HT3 receptor

agonist, that does not belong to the tryptamine-derived category is 4-amino-(6-chloro-2pyridyl)-1piperidine hydrochloride, more commonly known as SR 57227A (28, Figure
13), which is a potent agonist that crosses the BBB.111
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Cl

2-Methyl 5-HT (26)

5-HTQ (27)

SR 57227A (28)

Ki ~ 1300 nM

Ki ~ 75 nM

Ki ~ 103-150 nM

Figure 13. 5-HT3 receptor agonists and partial agonists.109,111

Phenylbiguanide (29; Table 4) is a low affinity 5-HT3 receptor agonist (Ki~1000
nM) that falls into the arylbiguanide classification.112 Structure-affinity studies have
shown that introduction of a chloro group at the 2-, 3-, or 4-position results in higher
binding affinity, with meta-chlorophenylbiguanide (mCPBG) (30) having a Ki value of
about 17 nM (Table 4).11 Benz-fusion at the 3- and 4- positions of the phenyl ring as
seen with the 2-naphthyl analog (i.e. 31) mimics the effect of the 3-chloro group.11,113
Improvements in affinity from the parent phenylbiguanide were observed with di- and trichloro substitution of the phenyl ring.114 By adding an electron-withdrawing nitro group,
a five-fold increase in affinity was observed versus the phenylbiguanide.11,113 However,
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the addition of the electron-withdrawing 3-trifluoromethyl group resulted in lower
affinity, around the 700 nM range; similar results were observed with the addition of a
methyl substituent to phenylbiguanide.11,113,114

The high affinity of the N-(2-

phenylethyl)guanidine analog 52 supported the idea that the biguanide moiety was not
essential for binding.11 This led to a new series of structure-activity studies.
By shortening the biguanide chain, arylguanidines were created, with mchlorophenylguanidine (m-CPG or MD-354) (42; Table 4) as a lead compound with a
binding affinity at 5-HT3 receptors of Ki = 35 nM.11,113 The same types of structural
modifications were made to the arylguanidines as in the arylbiguanides, which displayed
similar results. For example, higher binding affinities were observed with di- and trichloro substituted phenyl rings (i.e. 48-50; Table 4), and high binding affinity was
observed upon benz-fusion as seen with the 2-napthyl analog (i.e. 43; Table 4).11,14,113
This information supports the concept that parallel structural changes result in parallel
shifts in affinity. Also, affinity decreased with the addition of 3-methyl or 3trifluromethyl substituents (i.e. 46, 47; Table 4).11 The 3-trifluromethyl substituent is
electron-withdrawing, which is seemingly favored, however it is much bulkier than the
chloro-substituted analogs, which may result in its lack of binding affinity when added to
phenylguanidine.115 Lipophilic substituents are favored at the 4-position, but only up to a
certain size, as wider lipophilic substituents decrease affinity.115

Table 4. Binding affinities of arylbiguanide and arylguanidine 5-HT3
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receptor

agonist/partial agonist derivatives.11,14,113-115
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2,340
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3-Cl
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12
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2-Cl
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4-Cl
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3-NO2

-----
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35

780

3-CH3

46
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700
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5,700
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37

0.4
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12

3,4-Cl

48

3.1

39

1.8

3,5-Cl

49

5

40

2.7

3,4,5-Cl

50

0.7

-----
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3-CF3, 4-Cl

51

36

-----

-----

-----

52

40

Few pharmacophore models have been proposed for 5-HT3
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receptor

agonists/partial agonists, and none include all the different types of ligands. Glennon et
al. proposed a pharmacophore model for ligands containing an indole moiety, stating that
the distance from the aromatic centroid to the terminal amine is pertinent for binding.116
Later, Yamada et al. proposed a 3-point pharmacophore model consisting of an aromatic
region, an adjacent nitrogen atom, and a terminal amine.117 However, a limitation to this
model is that it only deals with 5-HT3 receptor agonist binding at gut 5-HT3 receptors.117
Rault et al. proposed a more complex 5-point pharmacophore model using seven
different structural classes of ligands.95 This model consisted of two hydrogen bond
acceptors, an aromatic moiety, a hydrophobic group, and an ionizable site that
corresponds to the terminal amine.95 However, none of these models accounts for the
two major classes of 5-HT3 receptor agonist ligands: arylguanidines and arylbiguanides.
A current working pharmacophore model (Figure 14) proposed by Dukat
accounts for binding of arylbiguanides and arylguanidines. This model consists of N1
Steric
Block (?)

N

N1

N

B
A

Du

Substituents
Tolerated

Figure 14. Current working pharmacophore model for 5-HT3 receptor agonists and
partial agonists.14
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which is located 2.7Å from an aryl centroid (Du) (i.e. A), and a terminal amine located
4.5-4.9Å from Du (i.e. B).14 All three guanidine nitrogen atoms are believed to be
required, with limited substitution; the N1 position contains a steric block.14 Lastly, there
is a region where affinity can be enhanced with substituents at the meta and para
positions.14 However, this model might not account for rotameric binding, since metasubstitution is preferred and two meta positions are present: the 3- and 5- position.115
Further studies are required to resolve this problem.

E. Quantitative Structure-Activity Relationships
Pharmacophore models are extremely helpful in predicting the behavior of new
molecules. Although, they are in fact, “just a model”, information from a pharmacophore
model can be helpful in the design of new ligands for particular receptors.

The

correlation between the biological activities of drugs with their physiochemical properties
is known as quantitative structure-activity relationships (QSAR), which is employed to
create pharmacophore models.118

Methods used to describe structure-activity

relationships include comparative molecular field analysis (CoMFA) and comparative
molecular similarity indices analysis (CoMSIA).
In general, development of pharmacophore models usually separates agonists and
antagonists, as agonists generally stabilize the active conformation of the receptor,
whereas antagonists stabilize the inactive conformation.118 Therefore, by placing both
agonists and antagonists into the same receptor model, the predictability of the model
might be low due to opposing biological factors.
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In order to create a pharmacophore model using either CoMFA or CoMSIA, a
“training set” of ligands with known biological activity is aligned within a fixed lattice.119
This set should exemplify all types of ligand substituents equally (e.g. electronwithdrawing groups, electron-donating groups, bulky substituents), in all possible
substitution locations. Once aligned, a partial least squares analysis is conducted to
correlate the field values with biological data, usually binding affinity.118 The “fit” of the
binding affinity values is expressed by the squared correlation coefficient, r2 which
usually is high if the ligands are well aligned.118

The predictability of the model is

determined through cross-validation, and is expressed as q2.118 Predictability values of
0.6 and above exemplify a “good model”, which can be used to predict the binding
affinity of new receptor ligands.119 The higher the q2 value, the better the model should
be at predicting the binding affinity of new ligands. The quality of this model can be
verified using a test set of compounds not included in the training set, but for which
biological data are known. If predicted binding affinities are similar to the actual binding
affinities of test set compounds, then this further validates the predictability of the
model.118
Other than predicting the binding affinity of new receptor ligands, QSAR models
can assist in the design of new ligands. This is due to the fact that CoMFA and CoMSIA
studies provide important information about the location of favorable and unfavorable
substituents. For example, CoMFA studies provide information to where electrostatic
fields are favorable or unfavorable, as well as to favorable and unfavorable steric bulk
regions.119

Once again, this information is based solely on ligands used in the training
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set employed to create the model. CoMSIA studies also give information about the
electrostatic and steric regions as well as hydrophobic, H-bond donor, and H-bond
acceptor regions that are favorable or unfavorable.120 With this information, the binding
affinity of new compounds can be predicted, or novel ligands can be designed through
analysis of favorable regions.

F. Behavioral Assays
There are several different rodent behavioral studies used to characterize
stimulant drugs including drug discrimination, self-administration, and locomotor activity
studies. Stimulants can act as discriminative stimuli in a drug discrimination (DD)
paradigm from which information can be obtained on a drug’s duration of action, time of
onset, mechanism of action, potency, and structure-activity relationships.121

Self-

administration studies are used to determine the reinforcing efficacy of the drug.122 Since
it is already known that behavioral stimulants have a central stimulatory effect which
results in changes in motor activity, locomotor activity assays are used to evaluate this
change.
Locomotor activity assays are conducted in square transparent chambers
surrounded by infared photo detectors; one bank of detectors measures activity at the
plane of the floor, whereas another is positioned centimeters above the floor to measure
vertical activities.123 These measure the coordinates of an animal’s location, as well as
the type of motion.123 Stimulants commonly increase motor activity such as the amount
of movement.

Some commonly analyzed parameters induced by stimulants include
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movement time, distance, velocity, and episodes. Movement time is the sum of time of
all movements in the floor plane as measured in seconds.123 For example, if mouse
movements were analyzed for 2700s, but the animal only moved a total of 1200s, the
latter would be considered its movement time.123 Movement distance is the sum of all
vector coordinate changes in the floor plane, and movement episodes are total
movements in the floor plane.123 So, if a mouse continues to walk for one minute, then
stops, this equates to one movement episode, whereas every centimeter the mouse walked
in that one episode is counted in movement distance.123 An average of the movement
time and movement distance can be calculated as velocity (cm/min), which is considered
the average speed of floor-plane coordinate-change defined movements.123

Typical

results for stimulants include increases in movement distance and movement time, but a
decrease in movement episodes. These same parameters (time, distance, and episodes)
can be applied to vertical entries, more commonly known as “rearing”, which includes
entries in the vertical plane that activate the upper infared photo-detectors.123
Some stimulant parameters that give insight into anxiolytic versus anxiogenic
activity are margin distance, margin time, center distance, center time, and center entries.
Margin distance is the same as movement distance, but is only calculated within a 2.5beam-margin-of-space toward the interior walls.123 Margin time is the amount of time
spent within this same margin of space.123 Mice that tend to stay near the margin display
thigmotaxis, which can be related to either anxiety or agoraphobia.124,125 Center distance
and center time are the distance, in centimeters, and time, in seconds, spent in the center
arena.123 Center episodes include the number of times the mouse enters the center arena,

123

characterized by anything outside of the 2.5-beam-margin-of-space.
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The more time

spent near the margins is characterized as an anxiogenic-like effect as the mouse is
thought to be more fearful.123 When the opposite occurs, where the mouse spends more
time in the center of the chamber, the animal is thought to be displaying anxiolytic-like
character.123
As in most behavioral assays, the actions of a test drug (i.e., stimulant) are
compared to the actions induced by saline. All drug administration parameters remain
the same such as duration of test, route of administration, pre-injection time, as well as
habitat conditions. When the study is complete, the results are analyzed using a one-way
analysis of variance (ANOVA) test on the mean response of each parameter, followed by
a post-hoc test to determine statistical significance.123 Results from many stimulant
studies result in an inverted U-shaped function, due to the fact that locomotor activity
increases as stimulant dose increases; however, after a certain dose, the effect either
remains steady or decreases.126 This type of behavioral assay should provide insight into
the effects of stimulants as well as other drugs on mouse locomotor activity.

III. Specific Aims

Psychomotor stimulants such as (+)amphetamine (2), (+)methamphetamine (3),
and cocaine (1) increase dopamine levels which, in turn, can increase locomotor activity
when administered to rodents. However, recent studies have shown that activation of
serotonin systems, more specifically 5-HT3 receptors, may modulate dopamine release.
5-HT3 receptor agonists have been shown to release dopamine in the striatum and nucleus
accumbens.127,128 5-HT3 receptor antagonists such as tropisetron (17; previously known
as ICS 205-930), zacopride (18), and MDL 72222 (15) attenuate stimulant parameters
when co-administered with acute treatments of cocaine in locomotor activity studies
using rats.129 The 5-HT3 receptor antagonist ondansetron (19) was able to attenuate the
effects of chronic treatment of cocaine and acute treatment of amphetamine on
hyperlocomotion.130,131 Similar results were observed using mice with acute treatments
of cocaine in combination with tropisetron (17) and zacopride (18).132 These data, as well
as other studies, suggest that 5-HT3 receptor agonists might indirectly increase dopamine
levels, whereas 5-HT3 receptor antagonists decrease dopamine levels, in different areas of
the brain.9
MD-354 (42; Figure 15) is a 5-HT3 receptor partial agonist that binds at 5-HT3
receptors with rather high affinity (Ki = 35 nM).11
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MD-354 (42) behaves both as an
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agonist and antagonist in different assays, with antagonist activity being more commonly
associated with higher doses, such as in antagonizing cisplatin-induced emesis.133

NH
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NH2

Cl

MD-354 (42)
Figure 15. Structure of the arylguanidine mCPG, more commonly known as MD-354.

One purpose of the present studies was to determine the effects of MD-354 (42)
on the locomotor actions of psychomotor stimulants; that is, might MD-354 potentiate (or
antagonize) the locomotor effects of (+)amphetamine? Previous data have shown that
MD-354, at doses of 1.0-10 mg/kg, does not produce a statistically significant difference
on any locomotor parameter.12 When administered alone, MD-354 behaves like saline.
But, if in combination with psychomotor stimulants it potentiates the drug’s locomotor
effects, MD-354 might be used as a form of drug replacement therapy. Drug replacement
therapy consists of combination treatment to wean a patient off the abused drug by
decreasing the dose of the drug of abuse while maintaining its positive effects due to its
combination with another non-stimulant drug.
Behavioral effects of MD-354 (42), as well as of several stimulants, will be
analyzed using a mouse locomotor activity assay.

(+)Amphetamine (2) and
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(+)methamphetamine (3) are phenylalkylamine stimulants with similar mechanisms of
action. Therefore, results should be similar, except that methamphetamine is a more
potent stimulant. These data will be compared to those obtained with cocaine (1), a nonphenylalkylamine stimulant with a different mechanism of action (reuptake blocker,
cocaine, versus substrate releaser). DOM (10) will be used as control, because it is
structurally similar to amphetamine, but is a non-stimulant phenylalkylamine
hallucinogen.
Dose response curves will be obtained for each drug to determine an effective
dose, which is a dose that produces a statistically significant effect versus saline. An
effective dose will be used in combination studies with varying doses of MD-354 (42).
The preinjection times, as well as the recording-time of the assays, will be determined
based on each drugs’ known onset of action and duration of action determined from
literature data.

Statistical analysis will be performed on commonly used stimulant

parameters such as movement distance, movement time, and movement episodes, as well
as other informative parameters (center distance, center time, center entries, margin
distance, margin time, and vertical entries). Potentiation of stimulant parameters (i.e., an
increase in movement distance and movement time or a decrease in movement episodes)
when MD-354 is administered in combination with an effective stimulant dose, would
suggest that MD-354 (42) is working through an agonist mechanism.

However,

attenuation of stimulant parameters would indicate an antagonist mechanism of action.
To further support or refute the determined mode of action of MD-354 (42), a
combination study of (+)amphetamine (2) and the 5-HT3 receptor antagonist ondansetron
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(19) will be performed. Since MD-354 is a partial agonist, it may behave as 5-HT3
receptor agonist, which should increase dopamine levels (increasing locomotor activity),
or as a 5-HT3 receptor antagonist, which could have the opposite effect. If the results of a
combination study of a 5-HT3 receptor antagonist (e.g. ondansetron) with
(+)amphetamine are similar to those obtained with MD-354 (42) in combination with
(+)amphetamine (2), then MD-354 could be working through a 5-HT3 receptor antagonist
mode of action. However, if results differ from what is shown in the combination of
MD-354 (42) with the stimulants, then MD-354 may be working through a 5-HT3
receptor agonist mechanism.
This idea will further be evaluated by conducting a similar study using a 5-HT3
receptor agonist, SR 57227A (28); a combination study of (+)amphetamine (2) and SR
57227A will be performed. If the results of the combination study are similar to those
observed using (+)amphetamine in combination with MD-354 (42), then MD-354 may be
working through a 5-HT3 receptor agonist mechanism, which should further support or
refute the data found in the combination study of ondansetron with (+)amphetamine.
Since

the

phenylalkylamine

stimulants

(+)amphetamine

(2)

and

methamphetamine (3) work through a different mechanism of action than the nonphenylalkylamine stimulant cocaine (1), similar results from combination studies with
MD-354 (42) may or may not be observed.

This could be due to differences in

mechanism of action, instead of the overall effect of increased synaptic dopamine levels.
The data from these studies will be compared to the combination studies of cocaine with
MD-354 to determine if MD-354 is working through a 5-HT3 receptor agonist or 5-HT3
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receptor antagonist mechanism of action. This will be compared to the effects obtained
in combination studies with amphetamine to determine if MD-354 behaves similarly with
phenylalkylamine stimulants as with non-phenylalkylamine stimulants (which work
through different mechanisms of action).
Combination studies will also be conducted using the 5-HT3 receptor agonist SR
57227A (28) in combination with cocaine as well as the 5-HT3 receptor antagonist
ondansetron (19) in combination with cocaine to determine if MD-354 (42) is working
through a 5-HT3 receptor agonist or antagonist mechanism. This study will help
determine whether MD-354 is behaving similarly in combination with cocaine as with
(+)amphetamine. Differences in the two studies once again could be associated with the
different mechanisms of action of the two psychomotor stimulants.
Since DOM (10) is a hallucinogen instead of a stimulant, locomotor activity
parameters such as movement distance or movement time might not increase following
DOM administration. However, consistent with what is known about hallucinogens,3
DOM might increase vertical entries (“rearing”).
MD-354 does not produce a locomotor stimulant effect by itself.12 Either it is
devoid of such action or MD-354 may not penetrate the BBB (i.e., it is assumed that a
central action is responsible for locomotor stimulation). MD-354 has a Log P value of
-0.64 which may prevent it from crossing the blood-brain barrier.13 Compounds with low
Log P values such as MD-354 may cross the BBB, however BBB penetration is more
commonly observed with compounds having a Log P value between 1.5-2.5.134
Therefore, a more lipophilic compound, the methyl carbamate analog of MD-354 (42),

135

will be synthesized and tested as a prodrug.
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Data from pharmacological assays

suggested that the methyl carbamate analog of MD-354 acted similarly to MD-354.12
This could be a result of insufficient lipophilicity, causing difficulty in crossing the BBB,
or that hydrolysis to MD-354 (42) occurred before it was able to cross the BBB.135
Therefore, another purpose of the present study is to synthesize more lipophilic
carbamate analogs of MD-354 that might act as prodrugs of MD-354 (Figure 16). These
carbamate analogs include the phenyl carbamate 53, the phenyl carbamate with an
electron-withdrawing group, 4-chlorophenyl carbamate 54, and the phenyl carbamate
with an electron-donating group, 4-methoxyphenyl carbamate 55. Although the Log P
values of these three carbamates are currently unknown, because they have yet to be
prepared, they can be predicted; using conversion ratios with the predicted Log P value of
MD-354 versus its known Log P value (octanol/water), the predicted Log P values of the
phenyl carbamates can be compared to MD-354. The phenyl carbamate was predicted to
have a Log P value of 1.62 which is greater than that of MD-354 (42) and falls within the
range of values which usually allows an agent to cross the BBB. Addition of the
electron-withdrawing chloro-group to the phenyl carbamate 54 increases lipophilicity,
with a predicted Log P value of 1.83. The addition of the electron-donating methoxygroup to the phenyl carbamate (i.e., 55) decreases lipophilicity slightly (Log P = 1.56)
from the phenyl carbamate 53. Since all three of the carbamates had predicted Log P
values in the range of 1.5-2.5, they should all cross the BBB, as they are predicted to be
more lipophilic than MD-354. These three carbamates should also display differences in
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rates of hydrolysis based on differences in hydrolytic stability due to the addition of
electron-donating and electron-withdrawing groups to the phenyl carbamate 53.

Cl

HN

NH

O

NH
N
H

O

HN

Cl

Cl

53

O
N
H

NH
O

HN

OCH3

O
N
H

O

Cl

54

55

Figure 16. Three proposed carbamate analogs of MD-354.

Once synthesized, the carbamates will be tested in rodent locomotor activity
assays. These carbamates should be more lipophilic than MD-354 (vide supra), should
more readily penetrate the BBB than MD-354 because of their increased lipophilicity,
and should be hydrolyzed to MD-354 in vivo by brain tissue esterases. Thus, if MD-354
possesses latent stimulant properties but simply does not penetrate the BBB, then more
lipophilic carbamates might produce locomotor stimulation.
In addition to the synthesis of the carbamate analogs, a conformationally
constrained analog of MD-354 (42) will be synthesized. Previous literature reported the
synthesis of 2-amino-7-chloro-3,4-dihydroquinazoline (56);13 however, a review of
available data suggested that the structure may have been misassigned and was actually
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the 6-chloro analog (i.e., 57). Therefore, 2-amino-6-chloro-3,4-dihydroquinazoline (57)
will be synthesized and compared to the earlier sample for clarification of structure.
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Figure 17. Conformationally constrained analogs of MD-354.

Once the correct structure (i.e., 56 or 57) is identified, this constrained analog as
well as 2-amino-5-chloro-3,4-dihydroquinazoline (58)135 will be used to further develop
and test our current working pharmacophore model for 5-HT3 receptor agonists and
partial agonists (as shown in Figure 14).

The use of conformationally-constrained

analogs in the working pharmacophore model is necessary to account for rotameric
binding. Some arylguanidine and arylbiguanide analogs contain substituents at the metaposition. However, it is not known at which meta position the substituents are located:
the 3-position or the 5-position. This is due to the fact that rotameric binding might occur
between the N1-position of the guanidine moiety and the phenyl ring (Figure 14). By
examining conformationally-constrained analogs, rotameric binding can be accounted
for, indicating at which meta-position a chloro group is more favorable for binding.
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A final goal of this work is to examine the quantitative structure-activity
relationships (QSAR) for the binding of arylguanidines and arylbiguanides at 5-HT3
receptors. As well as the conformationally-constrained analogs, about 40 other
arylguanidine and arylbiguanide analogs will be employed as the training set. This
training set will be aligned and analyzed using Comparative Molecular Field Analysis
(CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). Results
will be validated using a test set of five compounds not included in the training set, but
for which binding data are available. These studies will attempt to identify regions
favorable for steric, electrostatic, and hydrophobic interactions. This information will be
used to predict the binding affinity of five new analogs that have been synthesized in our
laboratories, binding data for which are not yet available.
The overall focus of these studies is to determine the effect of MD-354 (42) on
psychomotor stimulants, to synthesize phenyl carbamate analogs of MD-354, and
evaluate them in the mouse locomotor activity assay in order to determine whether or not
MD-354 penetrates the BBB and lacks stimulant effect or possesses stimulant-like
activity but does not cross the BBB. Another goal is to prepare a conformationallyconstrained arylguanidine and conduct QSAR studies to further develop our current
working pharmacophore model for 5-HT3 receptor ligands.
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IV. Results and Discussion
A. Behavioral Studies
1. Results
a) MD-354 (42)
Our laboratory has previously shown that, when administered alone, MD-354 (42)
produces saline-like effects in the mouse locomotor activity assay.12 In the present
investigation, to more thoroughly document this effect, locomotor activity assays were
conducted using i.p. injection doses of 1.0, 3.0, 6.0, and 10 mg/kg of MD-354 (42) with a
30-min pre-injection time, and a 45-min recording-time, as well as a 0-min pre-injection
time and a 1-h recording-time. Current data are in agreement with, and extend, that in the
literature; MD-354 (42) did not show a statistically significant difference versus saline in
the measured stimulant parameters [e.g. movement episodes, movement time (Figure 18),
movement distance, or vertical entries (data not shown)].
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Figure 18. Effect (± S.E.M.) of MD-354 (42) (30-min pre-injection time) on total
movement episodes and total movement time with a 45-min recording-time (n = 6
mice/treatment).
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Other parameters analyzed, such as margin time (Figure 19) and center time
(Figure 19), as well as, margin distance, center distance, or center entries (data not
shown) also lacked a statistically significant difference versus saline. It is important to
note that mice injected with MD-354 (42) or saline typically spent more time around the
margin of the chamber than in the center as shown in Figure 19. These data support the
notion that mice normally display as much anxiogenic-like activity in the presence of
MD-354 as they do following administration of saline alone.
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Figure 19. Effect (± S.E.M.) of MD-354 (42) (30-min pre-injection time) on total
margin time and total center time with a 45-min recording-time (n = 6 mice/treatment).
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b) Ondansetron (19)
MD-354 is a 5-HT3 receptor partial agonist that can display both agonist and
antagonist character (vide supra). The purpose of the current study was to determine the
effect of MD-354 (42) on the locomotor effects of psychomotor stimulants. To further
characterize the function of MD-354 (42), a 5-HT3 receptor agonist and a 5-HT3 receptor
antagonist were used in combination with psychomotor stimulants. Comparison of the
results from a combination of MD-354 with stimulants, to that of SR 57227A (28), a 5HT3 receptor agonist, and ondansetron (19), a 5-HT3 receptor antagonist, with stimulants,
should provide insight about the function of MD-354 (42). Therefore, dose-response
studies were conducted with ondansetron (19) and SR 57227A (28), alone, and in
combination with the stimulants amphetamine (2) and cocaine (1).
The present study analyzed the locomotor activity of the 5-HT3 receptor
antagonist ondansetron (19) at doses 0.1, 0.5, and 1.0 mg/kg. The protocol remained the
same, with a 30-min pre-injection time followed by a 45-min recording-time. When
administered alone, ondansetron (19) produced saline-like effects on stimulant
parameters (movement episodes, movement time, movement distance, and vertical entries
as shown in Figure 20) as well as on non-stimulant parameters (margin distance, margin
time, center distance, center time, and center entries, as shown in Figure 21), which was
consistent with literature data indicating that ondansetron lacks central stimulant action
when administered via the i.p. route.136
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Figure 20. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) on total movement episodes, total movement time, total movement distance, and
vertical entries versus saline with a 45-min recording-time (n = 6 mice/treatment).
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Figure 21. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) on total margin distance, total margin time, total center distance, total center time,
and total center entries versus saline with a 45-min recording-time (n = 6 mice/treatment).
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c) SR 57227A (28)
Locomotor activity assays were conducted with various doses of the agonist SR
57227A (28) (1.0, 3.0, and 10 mg/kg) which were injected i.p. 30 min prior to the test
with a recording-time of 45 min. The same parameters were analyzed as with MD-354
(42) with similar results; SR 57227A (28) produced saline-like effects as shown in Figure
22. Analysis of center entries using a t-test instead of one-way ANOVA showed that SR
57227A (28) had a statistically significant effect versus saline at a 1.0 mg/kg dose, as SR
57227A suppressed center entries, suggesting that SR 57227A displayed anxiogenic-like
behavior in mice (Figure 23). Even though SR 57227A doses were not statistically
significant versus saline for either center distance or center time, the observed effect
occurred in a dose-responsive manner, as a 1.0 mg/kg dose of SR 57227A was indicative
of the upward slope of a dose-response curve.
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Figure 22. Effect (± S.E.M.) of varying doses of SR 57227A (28) (30-min pre-injection
time) on total movement episodes, total movement time, total movement distance, and
total vertical entries versus saline with a 45-min recording-time (n = 7 mice/treatment).
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Figure 23. Effect (± S.E.M.) of varying doses of SR 57227A (28) (30-min pre-injection
time) on total margin distance, total margin time, total center distance, total center time,
and total center entries versus saline with a 45-min recording-time (n = 7 mice/treatment).
Asterisk denotes statistical significance compared to the saline control group; *P<0.05; ttest.
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d) (+)Amphetamine (2)
i. Dose Response
A locomotor activity assay was performed with varying doses of (+)amphetamine
(2) to determine an effective dose (i.e., a dose that produces a statistically significant
effect versus saline). In the present investigation, (+)amphetamine doses of 0.3, 1.0, 2.0,
3.0, and 6.0 mg/kg were injected to the mice, which were immediately placed into the
chamber (0-min pre-injection time) with a recording-time of 45 min. After 15 min,
(+)amphetamine (2) doses of 3.0 and 6.0 mg/kg produced a statistically significant
stimulant effect on movement episodes, movement time, and movement distance (Figure
24). Similar effects were observed for the entire duration of the experiment.
Upon analyzing other parameters, it was observed that (+)amphetamine (2)
produced no statistically significant difference versus saline on vertical entries, margin
time, center distance, center time, and center episodes (Figure 25). However, doses of
3.0 and 6.0 mg/kg of (+)amphetamine statistically significantly increased margin distance
during the entire recording-time as shown in Figure 24.
In order to visualize the stimulant effect of an effective dose of (+)amphetamine
(2), a picture of the actual movements made by the animals following a 3.0 mg/kg dose of
(+)amphetamine versus saline is shown in Figure 26.
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Figure 24. Effect (± S.E.M.) of (+)amphetamine (2) injected 0 min prior to examination
on total movement episodes, total movement time, total movement distance, and total
margin distance with a 45-min recording-time (n = 6-8 mice/treatment). Asterisk denotes
a significant difference compared to the saline control group; **P<0.01, ***P<0.001;
one-way ANOVA (F5,43 = 15.46 (movement episodes), F5,43 = 7.44 (movement time),
F5,43 = 7.44 (movement distance), F5,43 = 8.05 (margin distance)) followed by a NewmanKeuls post-hoc test.
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Figure 25. Effect (± S.E.M.) of (+)amphetamine (2) injected 0 min prior to examination
on total vertical entries, total margin time, total center distance, total center time, and
total center entries with a 45-min recording-time (n = 6-8 mice/treatment).
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A

B

Figure 26. Graphical representation of the movement distance for the entire duration (45
min) of the experiment. A) The actual locomotion of a mouse when injected with saline.
B) Stimulation by injection of an effective dose of (+)amphetamine (3.0 mg/kg).
ii. Combination of (+)Amphetamine (2) and MD-354 (42)
An effective dose of (+)amphetamine (3.0 mg/kg) was examined in combination
with varying doses of MD-354 (42). The protocol entailed injecting varying doses of
MD-354 (1.0, 3.0, and 10 mg/kg) i.p. 30 min prior to the test. (+)Amphetamine (2) was
injected 0 min prior to the experiment and the mice were placed in the chamber with a
45-min recording-time.

Combination of MD-354 with an effective dose of

(+)amphetamine

potentiated

neither

or

modulated

the

stimulant

effect

of

(+)amphetamine. For both stimulant and non-stimulant parameters (movement episodes,
movement time, movement distance, vertical entries, margin distance, margin time,
center distance, center time, and center entries), which were separated for convenience,
results were essentially the same following administration of (+)amphetamine (2) alone,
and following administration of (+)amphetamine in combination with doses of MD-354
(42) (Figure 27 and Figure 28).

Although combinations of MD-354 with
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(+)amphetamine were not statistically significant, the effects of MD-354 on
(+)amphetamine were dose dependent for the parameters center distance and center
entries.
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Figure 27. Effect (± S.E.M.) of combination of (+)amphetamine (2) (3.0 mg/kg) with
varying doses of MD-354 (42) on total movement episodes, total movement time, total
movement distance, and vertical entries following a 30-min pre-injection time of MD-354
and a 45-min recording-time (n = 7-8 mice/treatment).
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Figure 28. Effect (± S.E.M.) of combination of (+)amphetamine (2) (3.0 mg/kg; 0-min
pre-injection time) with varying doses of MD-354 (42) (30-min pre-injection time) on
total margin distance, total margin time, total center distance, total center time, and total
center entries with a 45-min recording-time (n = 7-8 mice/treatment).
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A similar study was conducted using doses of 1.0, 3.0, and 10 mg/kg of MD-354
(42) (30-min pre-injection time) in combination with a moderate dose of (+)amphetamine
(2) (2.0 mg/kg; 0-min pre-injection time). The obtained results were similar to those
observed with an effective dose of (+)amphetamine (3.0 mg/kg) alone, on all parameters
observed (data not shown).

iii. Combination of (+)Amphetamine (2) and Ondansetron (19)
The effect of the 5-HT3 receptor antagonist ondansetron (19) on the actions of an
effective dose of (+)amphetamine (2) was examined. Doses of 0.1, 0.5, and 1.0 mg/kg of
ondansetron were injected i.p., 30 min prior to the test. (+)Amphetamine (2; 3.0 mg/kg)
was injected 0 min before the test and a 45-min recording-time was employed. In
combination, ondansetron (19) neither potentiated nor modulated the action of an
effective dose of (+)amphetamine.

For parameters analyzed (movement episodes,

movement distance, movement time, vertical entries, margin distance, margin time,
center time, and center entries), the effect of ondansetron pre-treatment on the actions of
(+)amphetamine were not different than that following administration of (+)amphetamine
alone (Figure 29 and Figure 30), except at a 1.0 mg/kg dose of ondansetron, which
potentiated the effect of (+)amphetamine on the parameter center distance (Figure 30).
Since doses of ondansetron in combination with (+)amphetamine decreased margin
distance and margin time, while increasing center measures, ondansetron in combination
with (+)amphetamine was producing an anxiolytic-like effect. Even though this effect
was not statistically significant in most cases, it was dose dependent.
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Figure 29. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) in combination with 3.0 mg/kg of (+)amphetamine (2) (0-min pre-injection time)
on the stimulant parameters of total movement episodes, total movement time, total
movement distance, and total vertical entries with a 45-min recording-time (n = 6-8
mice/treatment).
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Figure 30. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) in combination with 3.0 mg/kg of (+)amphetamine (2) (0-min pre-injection time)
on total margin distance, total margin time, total center distance, total center time, and
total center entries with a 45-min recording-time (n = 6-8 mice/treatment).
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iv. Combination of (+)Amphetamine (2) and SR 57227A (28)
To determine the effects of the 5-HT3 receptor agonist SR 57227A (28) on the
effects produced by a moderate dose of (+)amphetamine (2) (2.0 mg/kg), studies with
combinations of both drugs were conducted. In the present investigation, SR 57227A
(28) was administered 30 min prior to testing at i.p. doses of 1.0, 3.0, and 10 mg/kg.
(+)Amphetamine (2) was administered 0 min prior to test. Within 15 min of the initiation
of the experiment, potentiation of stimulant effects was observed; the effects lasted 30
min.

The parameters affected by this combination included movement episodes,

movement time, movement distance and margin distance for the first 15-min interval, and
only movement episodes and movement distance for the second 15-min interval. For the
parameters mentioned above, potentiation occurred at a 3.0 mg/kg dose of SR 57227A
(28) with 2.0 mg/kg of (+)amphetamine (2), except movement episodes, where
potentiation was observed with both 3.0 mg/kg and 10 mg/kg doses of SR 57227A
(Figure 31). The other parameters (vertical entries, margin time, center distance, center
time, and center entries) revealed amphetamine-like effects throughout the entire
experiment (Figure 32).

Comparison of the data indicated that SR 57227A (28)

potentiated the stimulant effect of a moderate dose of (+)amphetamine (2) and that this
potentiation occurred in a dose-dependent manner.
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Figure 31. Effect (± S.E.M.) of varying doses of SR 57227A (28) (injected 30 min prior
to examination) on a moderate dose of (+)amphetamine (2) (injected 0 min prior to
examination) after the first 15-min interval of a 45-min protocol (n = 8 mice/treatment).
Asterisk denotes a significant difference compared to a 2.0 mg/kg dose of
(+)amphetamine; *P<0.05, **P<0.01, and ***P<0.001; one-way ANOVA (F4,41 = 19.52
(movement episodes), F4,41 = 16.15 (movement time), F4,41 = 13.68 (movement distance),
and F4,41 = 10.36 (margin distance)) followed by a Newman-Keuls post-hoc test.
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Figure 32. Effect (± S.E.M.) of varying doses of SR 57227A (28) (30-min pre-injection
time) on a moderate dose of (+)amphetamine (2) (2.0 mg/kg, 0-min pre-injection time) on
total vertical entries, total margin time, total center distance, total center time, and total
center entries with a 45-min recording-time (n = 6-8 mice/treatment).
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e) (+)Methamphetamine (3)
i. Dose Response
A mouse locomotor activity assay was conducted to determine an effective dose
of (+)methamphetamine (3). Varying doses of (+)methamphetamine (0.3, 1.0, 1.5, 3.0
and 10 mg/kg) were injected i.p. 0 min before the mice were placed in the chamber with a
recording-time

of

60

min.

Within

the

first

15-min

interval,

doses

of

(+)methamphetamine (3) displayed statistically significant stimulant effects versus saline.
These effects varied between different doses and different parameters for the entire 60min trial. Upon analysis of stimulant parameters, (+)methamphetamine (3) produced a
statistically significant stimulant effect versus saline at doses of 1.5, 3.0 and 10 mg/kg on
movement episodes, movement time, and movement distance within the first 15 min
(Figure 33) and on various doses for the same three parameters for the entire duration of
the experiment (Figure 34). These stimulant effects were observed at lower doses, than
with those of (+)amphetamine, supporting the idea the (+)methamphetamine is the more
potent stimulant. (+)Methamphetamine (3) also produced a statistically significant effect
on vertical entries and margin distance from the first 15-min interval throughout the
experiment (Figure 34). Center entries were statistically significantly increased within 30
min (data not shown) and continued so for the duration of the 60-min experiment (Figure
34).

Parameters not affected by varying doses of (+)methamphetamine (3) include

margin time, center distance, and center time (Figure 35).
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Figure 33. Effect (± S.E.M.) of varying doses of (+)methamphetamine (3) (0.3, 1.0, 1.5,
3.0, and 10 mg/kg; 0-min pre-injection) on the stimulant parameters of movement
episodes, movement time, and movement distance within 15 min of a 60-min protocol (n
= 6-8 mice/treatment). Asterisk denotes a significant difference compared to the saline
control group; **P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F5,39 = 14.83
(movement episodes), F5,39 = 15.49 (movement time), F5,39 = 10.08 (movement distance))
followed by a Newman-Keuls post-hoc test.
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Figure 34. Effect (± S.E.M.) of varying doses of (+)methamphetamine (3) (0-min preinjection) on total movement episodes, total movement time, total movement distance,
total vertical entries, total margin distance, and total center entries with a 60-min protocol
(n = 6-8 mice/treatment). Asterisk denotes a significant difference compared to the saline
control group; **P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F5,39 = 13.58
(movement episodes), F5,39 = 14.63 (movement time), F5,39 = 25.01(movement distance),
F5,39 = 13.89 (vertical entries), F5,39 = 7.89 (margin distance), F5,39 = 5.16 (center entries))
followed by a Newman-Keuls post-hoc test.
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Figure 35. Effect (± S.E.M.) of varying doses of (+)methamphetamine (3) (0-min preinjection time) on total margin time, total center distance, and total center time with a 60min recording-time (n = 6-8 mice/treatment).
ii. Combination (+)Methamphetamine (3) and MD-354 (42)
The effect of varying doses of MD-354 (42) on an effective dose of
(+)methamphetamine (3) was examined. MD-354 (42) doses of 0.3, 1.0, 3.0, and 6.0
mg/kg were administered i.p. 0 min prior to the experiment. (+)Methamphetamine (1.5
mg/kg) was administered 0 min prior to the experiment and the recording-time was 1 h.
For all parameters analyzed, administration of MD-354 in combination with
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(+)methamphetamine neither potentiated nor modulated the stimulant effect of
(+)methamphetamine. A combination of MD-354 (42) and (+)methamphetamine (3)
produced similar effects as (+)methamphetamine administered alone. The parameters
analyzed included movement episodes, movement time, movement distance, vertical
entries, margin distance, margin time, center distance, center time, and center entries as
shown in Figure 36 and Figure 37.
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Figure 36. Effect (± S.E.M.) of varying doses of MD-354 (42) (0.3, 1.0, 3.0, and 6.0
mg/kg; 0-min pre-injection time) on an effective dose of (+)methamphetamine (3) (1.5
mg/kg; 0-min preinjection time) on total movement episodes, total movement time, total
movement distance, and total vertical entries with a 60-min recording-time (n = 6-8
mice/treatment).
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Figure 37. Effect (± S.E.M.) of varying doses of MD-354 (42) (0.3, 1.0, 3.0, and 6.0
mg/kg; 0-min pre-injection time) on an effective dose of (+)methamphetamine (3) (1.5
mg/kg; 0-min preinjection time) on total margin distance, total margin time, total center
distance, total center time and total center entries with a 60-min recording-time (n = 6-8
mice/treatment).
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A similar protocol was employed using a 3.0 mg/kg dose of (+)methamphetamine
(3) in combination with 1.0, 3.0, and 6.0 mg/kg doses of MD-354. The pre-injection and
recording-times remained the same, resulting in similar effects as observed with a
combination of 1.5 mg/kg (+)methamphetamine (3) and varying doses of MD-354 (42):
combination of MD-354 with (+)methamphetamine neither potentiated nor modulated the
stimulant effects of (+)methamphetamine (data not shown).

f) DOM (10)
i. Dose Response
A locomotor activity assay was conducted to determine an effective dose of DOM
(10) and to determine its effects on mouse locomotor actions. Varying doses of DOM
(0.3, 1.0, and 3.0 mg/kg) were injected i.p. 0 min before the mice were placed in the
chamber, with a recording-time of 60 min. After 15 min, DOM (10) behaved similarly to
saline at all administered doses. However, within 30 min of the experiment, movement
distance and margin distance were statistically significantly increased following all doses.
Within 45 min, doses of 0.3 and 1.0 mg/kg of DOM (10) statistically significantly
increased movement distance and margin distance. However, only a 0.3 mg/kg dose of
DOM (10) increased vertical entries.

Following 60 min post administration, DOM

increased locomotor activity on the parameters of movement time, movement distance,
vertical entries, and margin distance versus saline as shown in Figure 38. Throughout the
entire study, DOM produced a saline-like effect on the parameters of movement episodes,
margin time, center distance, center time, and center entries (Figure 39).
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Figure 38. Effect (± S.E.M.) of varying doses of DOM (10) (0-min pre-injection time)
on total movement time, total movement distance, vertical entries, and margin distance
with a 60-min recording-time (n = 6-8 mice/treatment). Asterisk denotes statistical
significance compared to the saline control group; *P<0.05, **P<0.01, ***P<0.001; oneway ANOVA (F3,28 = 3.5 (movement time), F3,28 = 5.03 (movement distance), F3,28 =
4.15 (vertical entries), F3,28 = 6.54 (margin distance)) followed by a Newman-Keuls posthoc test.
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Figure 39. Effect (± S.E.M.) of varying doses of DOM (10) (0-min pre-injection time)
on total movement episodes, total margin time, total center distance, total center time,
and total center entries with a 60-min recording-time (n = 6-8 mice/treatment).
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ii. Combination of DOM (10) and MD-354 (42)
The next step was to determine the effect of MD-354 (42) on an effective
behavioral dose of DOM (10). A study was conducted using 0.1, 1.0, 3.0, and 6.0 mg/kg
doses of MD-354 (42) (30-min pre-injection time) in combination with a 0.3 mg/kg dose
of DOM (10) (0-min pre-injection time). The recording-time of the experiment was 60
min.

Within 15 min of the initiation of the experiment, a low dose of MD-354 (0.1

mg/kg) antagonized the effect of DOM on movement distance, vertical entries, and center
entries (a 1.0 mg/kg dose of MD-354 also antagonized the effect DOM displayed on
vertical entries). As the experiment continued, MD-354 (42) antagonized various other
parameters at various doses.

Some parameters effected include movement time,

movement distance, vertical entries, margin distance, center distance, and center entries
as shown in Figure 40. The effect DOM (10) had on vertical entries alone and in
combination with MD-354 (42) is shown in Figure 41. Combination of MD-354 with
DOM produced similar results as DOM administered alone on movement episodes,
margin time, and center time throughout the duration of the experiment (as shown in
Figure 42).
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Figure 40. Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection
time) on an effective dose of DOM (10) (0.3 mg/kg; 0-min pre-injection time) on total
movement time, total movement distance, total vertical entries, total margin distance,
total center distance, and total center entries with a 60-min recording-time (n = 6-8
mice/treatment). Asterisk denotes statistical significance compared to a 0.3 mg/kg dose
of DOM; *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F5,41 = 2.74 (movement
time), F5,41 = 4.43 (movement distance), F5,41 = 5.31 (vertical entries), F5,41 = 4.49
(margin distance), F5,41 = 1.30 (center distance) F5,41 = 2.48 (center entries)) followed by
a Newman-Keuls post-hoc test.
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Figure 41. Graphical representation of vertical entries for the entire duration (60 min) of
the experiment. A) Vertical entries of mice when administered saline. B) Vertical entries
of mice when administered 0.3 mg/kg dose of DOM. C) Vertical entries of combination
of 1.0 mg/kg dose of MD-354 and 0.3 mg/kg dose of DOM.
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Figure 42. Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection
time) on an effective dose of DOM (10) (0.3 mg/kg; 0-min pre-injection time) on total
movement episodes, total margin time, and total center time with a 60-min recordingtime (n = 6-8 mice/treatment).
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g) Cocaine (1)
i. Dose Response
The present study was conducted to determine an effective dose of cocaine (1).
Varying doses of cocaine (1) (1.0, 3.0, 10, and 30 mg/kg) were administered i.p. 0 min
prior to the experiment. The mice were placed in the chamber and tested for 45 min.
Within the first 15 min, locomotor activity was statistically significantly decreased versus
saline on the stimulant parameter of movement episodes (30 mg/kg), whereas activity
was significantly increased for movement time (30 mg/kg) and movement distance (10
and 30 mg/kg) as shown in Figure 43, as well as following 10 and 30 mg/kg doses of
cocaine (1) on the non-stimulant parameters of margin distance and margin time (Figure
43). Statistically significant decreases in center distance and center time were observed
versus saline at doses of 10 and 30 mg/kg of cocaine (Figure 44). Within 30 min, the
only effects observed were statistically significant increases on the stimulant parameters
of movement episodes, movement time, movement distance, and margin distance. By 45
min, movement time, movement distance, and margin distance were still increased
following 10 and 30 mg/kg doses of cocaine, as well as statistically significantly increase
in vertical entries versus saline (Figure 45).

Overall, cocaine produced a saline-like

effect at all doses administered on total vertical entries, total margin time, total center
distance, total center time, and total center entries (Figure 46), however the effects on
vertical entries, center distance and center time were dose-dependent.
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Figure 43. Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time;
45-min recording-time) on movement episodes, movement time, movement distance and
margin distance within the first 15-min (n = 6-8 mice/treatment). Asterisk denotes
statistical significance compared to the saline control group; *P<0.05, **P<0.01,
***P<0.001; one-way ANOVA (F4,43 = 6.78 (movement episodes), F4,43 = 5.37
(movement time), F4,43 = 6.32 (movement distance), F4,43 = 6.45 (margin
distance))followed by a Newman-Keuls post-hoc test.
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Figure 44. Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time;
45-min recording-time) on margin time, center distance and center time within the first
15-min (n = 6-8 mice/treatment). Asterisk denotes statistical significance compared to the
saline control group; *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA (F4,43 = 4.91
(margin time) F4,43 = 4.36 (center distance), F4,43 = 4.91 (center time)) followed by a
Newman-Keuls post-hoc test.
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Figure 45. Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time;
45-min recording-time) on total movement episodes, total movement time, total
movement distance, total margin distance (n = 6-8 mice/treatment). Asterisk denotes
statistical significance compared to the saline control group; **P<0.01 and ***P<0.001;
one-way ANOVA (F4,43 = 5.09 (movement episodes), F4,43 = 7.67 (movement time), F4,43
= 9.02 (movement distance), F4,43 = 8.31 (margin distance)) followed by a NewmanKeuls post-hoc test.
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Figure 46. Effect (± S.E.M.) of varying doses of cocaine (1) (0-min pre-injection time;
45-min recording-time) on total vertical entries, total margin time, total center distance,
total center time, and total center entries (n = 6-8 mice/treatment).
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ii. Combination of Cocaine (1) and MD-354 (42)
The effect of varying doses of the 5-HT3 receptor partial agonist, MD-354 (42)
(1.0, 3.0, and 10 mg/kg) on an effective dose of cocaine (1) (10 mg/kg) was examined.
MD-354 (42) was administered 30 min prior to examination, followed by cocaine (1)
administered 0 min prior to examination.

The recording-time for the present

investigation was 45 min. Within the first 15 min, in combination with cocaine (1), MD354 (42) potentiated the stimulant effect that cocaine displayed when administered alone.
This potentiation was observed with a decrease in movement episodes and an increase in
movement time as shown in Figure 47. Within this first 15 min all other parameters
behaved similarly to cocaine when administered alone (data not shown).
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Figure 47. Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection
time) on a effective dose of cocaine (1) (10 mg/kg; 0-min pre-injection time) within the
first 15-min of the 45-min protocol (n = 6-8 mice/treatment). Asterisk denotes statistical
significance compared to a 10 mg/kg dose of cocaine; *P<0.05 and **P<0.01; one-way
ANOVA (F4,43 = 16.90 (movement episodes) and F4,43 = 23.73 (movement time))
followed by a Newman-Keuls post-hoc test.
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Within 30 min of the experiment, a separate set of parameters were affected.
Instead of stimulant parameters being potentiated as within the first 15 min, vertical
entries, center distance, and center entries were potentiated as shown in Figure 48.
Vertical entries were potentiated at all doses of MD-354 (42) versus cocaine (1), whereas
6.0 mg/kg dose of MD-354 in combination with cocaine potentiated the effect on the
parameters center distance and center entries versus cocaine alone (Figure 48).
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Figure 48. Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection
time) on an effective dose of cocaine (1) (0-min pre-injection) within 30 min of the 45min protocol (n = 6-8 mice/treatment). Asterisk denotes statistical significance compared
to a 10 mg/kg dose of cocaine; *P<0.05 and **P<0.01; one-way ANOVA (F4,43 = 17.92
(vertical entries), F4,43 = 2.37 (center distance), F4,43 = 5.88 (center entries)) followed by a
Newman-Keuls post-hoc test.
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Movement distance, margin distance, margin time, and center time were not
affected by the combination of MD-354 (42) with cocaine (1) at any dose combinations
administered. For these parameters, combination of MD-354 with an effective dose of
cocaine (10 mg/kg) produced a cocaine-like effect (Figure 49).
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Figure 49. Effect (± S.E.M.) of varying doses of MD-354 (42) (30-min pre-injection
time) on an effective dose of cocaine (1) (0-min pre-injection time) for total movement
distance, total margin distance, total margin time, and total center time with a 45-min
recording-time (n = 6-8 mice/treatment).
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iii. Combination of Cocaine (1) and Ondansetron (19)
The effect of varying doses of the 5-HT3 receptor antagonist ondansetron (19) was
examined in combination with an effective dose of cocaine (1).

Varying doses of

ondansetron (0.1, 0.5, and 1.0 mg/kg) were injected i.p. 30 min prior to the experiment.
A 10 mg/kg dose of cocaine was injected 0 min prior to the experiment; the recordingtime of the experiment was 45 min. Within the first 15 min only one parameter was
affected; movement episodes were suppressed by a 0.5 mg/kg dose of ondansetron (19)
as shown in Figure 50. The stimulant effect of cocaine was potentiated by addition of the
5-HT3 receptor antagonist ondansetron (19).
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Figure 50. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) on an effective dose of cocaine (1) (10 mg/kg; 0-min pre-injection time) observed
within the first 15-min of the 45-min protocol (n = 6-8 mice/treatment). Asterisk denotes
statistical significance compared to a 10 mg/kg dose of cocaine; *P<0.05; one-way
ANOVA (F4,40 = 8.11 (movement episodes)) followed by a Newman-Keuls post-hoc
test.
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Within 30 min, only one parameter was affected by the combination of
ondansetron (19) with cocaine (1); when administered together, ondansetron (0.5 and 1.0
mg/kg doses) potentiated the effect of cocaine on center entries as shown in Figure 51.
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Figure 51. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) on a 10 mg/kg dose of cocaine (1) (0-min pre-injection time) observed within 30min of the 45-min protocol (n = 6-8 mice/treatment). Asterisk denotes statistical
significance compared to a 10 mg/kg dose of cocaine; *P<0.05 and **P<0.01; one-way
ANOVA (F4,40 = 5.81 (center entries)) followed by Newman-Keuls post-hoc test.
Within 45 min of initiation of the experiment, the effect of ondansetron (29) on
cocaine (1) shifted to margin distance. The effect of cocaine was suppressed by 0.1 and
1.0 mg/kg of ondansetron in an inverted U-shape dose response manner as shown in
Figure 52.
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Figure 52. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) on a 10 mg/kg dose of cocaine (1) (0-min pre-injection time) observed within 45min (n = 6-8 mice/treatment). Asterisk denotes statistical significance compared to a 10
mg/kg dose of cocaine; *P<0.05; one-way ANOVA (F4,40 = 4.59 (margin distance))
followed by a Newman-Keuls post-hoc test.
Only one parameter was affected by the combination of ondansetron with cocaine
in each 15-min interval. However, upon analysis of the entire study, combination of
varying doses of ondansetron (19) with an effective dose of cocaine (1) neither
potentiated nor antagonized the effect of cocaine when administered alone. This was
observed for all parameters analyzed for total time of the experiment (movement
episodes, movement time, movement distance, margin distance, margin time, center
distance, and center time as shown in Figure 53 and Figure 54) except center entries
which were potentiated at 0.5 and 1.0 mg/kg doses of ondansetron. Although statistically
significant changes were not observed, the effects of ondansetron on cocaine were dose
dependent.
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Figure 53. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) in combination with an effective dose of cocaine (1) (0-min pre-injection time) on
total movement episodes, total movement distance, total movement time, total vertical
entries with a 45-min recording-time (n = 6-8 mice/treatment).
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Figure 54. Effect (± S.E.M.) of varying doses of ondansetron (19) (30-min pre-injection
time) in combination with an effective dose of cocaine (1) (0-min pre-injection time) on
total margin distance, total margin time, total center distance, total center time, and total
center entries with a 45-min recording-time (n = 6-8 mice/treatment).
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iv. Combination of Cocaine (1) and SR 57227A (28)
Combination studies of the 5-HT3 receptor agonist SR 57227A (28) with an
effective dose of cocaine on locomotor activity were conducted.

The present

investigation employed 1.0, 3.0, and 10 mg/kg doses of SR 57227A (28) (30-min preinjection time) in combination with a 10 mg/kg dose of cocaine (1) (0-min pre-injection
time) administered i.p. The recording-time of the experiment was 45 min. Within the
first 15 min, the stimulant effect of cocaine was potentiated as evidenced by increasing
the parameters of movement episodes and movement time. This effect was observed
following all three administered doses of SR 57227A (28) in combination with cocaine as
opposed to the effect observed with cocaine (1) administered alone (Figure 55). Also,
within the first 15-min interval, the effect of cocaine was antagonized by a 1.0 mg/kg
dose of SR 57227A. When administered alone, cocaine (1) suppressed center entries,
however in combination with SR 57227A (28), the number of center entries was
increased (Figure 55).
These were the only parameters influenced by the combination of varying doses
of SR 57227A with an effective dose of cocaine. For the duration of the experiment, the
combination of SR 57227A (28) and cocaine (1) behaved similarly to cocaine
administered alone for all parameters analyzed (movement episodes, movement time,
movement distance, vertical entries, margin distance, margin time, center distance, center
time and center entries as shown in Figure 56 and Figure 57).
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Figure 55. Effect (± S.E.M.) of SR 57227A (28) (30-min pre-injection time) on an
effective dose of cocaine (1) (0-min pre-injection time) within the first 15-min of the
experiment of a 45-min protocol (n = 6-8 mice/treatment). Asterisk denotes statistical
significance compared to a 10 mg/kg dose of cocaine; *P<0.05, **P<0.01, ***P<0.001;
one-way ANOVA (F4,40 = 20.38 (movement episodes), F4,40 = 25.01 (movement time),
F4,40 = 2.55 (center entries)) followed by Newman-Keuls post-hoc test.
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Figure 56. Effect (± S.E.M.) of SR 57227A (28) (30-min pre-injection time) in
combination with cocaine (1) (0-min pre-injection time) on total movement episodes,
total movement distance, total movement time, and vertical entries with a 45-min
recording-time (n = 6-8 mice/treatment).
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Figure 57. Effect (± S.E.M.) of SR 57227A (28) (30-min pre-injection time ) in
combination with cocaine (1) (0-min pre-injection time) on total margin distance, total
margin time, total center distance, total center time, and total center entries with a 45-min
recording-time (n = 6-8 mice/treatment).
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2. Discussion
The purpose of the present study was to determine the influence of the 5-HT3
receptor partial agonist MD-354 on the locomotor actions of psychomotor stimulants (as
5-HT3 receptor ligands have been shown to indirectly affect dopamine levels) and if this
effect could be characterized as acting through a 5-HT3 receptor agonist or 5-HT3
receptor antagonist mode of action. The present investigation was conducted in order to
determine the locomotor effects of the phenylalkylamine stimulant (+)amphetamine (2) in
combination with MD-354 (42), ondansetron (19), and SR 57227A (28) as compared to
similar tests using cocaine (1) (a non-phenylalkylamine stimulant) with the same 5-HT3
receptor ligands.

(+)Methamphetamine (3) (a structurally similar amphetamine

phenylalkylamine stimulant) and DOM (10) (a phenylalkylamine non-stimulant used as a
control) were also administered in combination with MD-354 to determine the effects of
MD-354 in combination with these drugs of abuse, on locomotor activity. The overall
effects of these agents and drug combinations are shown in Table 5.
Varying doses of the 5-HT3 receptor ligands were administered alone to determine
whether or not they bestowed an effect versus saline. When administered alone, MD-354
had no effect on mouse locomotor activity (Table 5). These data are consistent with and
further extend earlier findings. Dukat et al. investigated the effect of MD-354 (42) on
mouse locomotor activity at doses ranging from 1.0 to 10 mg/kg; results suggested that
MD-354 produces saline-like effects on locomotor activity.12 Ondansetron was found to
behave similarly to MD-354; the saline-like effect of ondansetron was consistent with
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a

Table 5. Summary of the effects of all drugs tested in the mouse locomotor activity assay.
Measure:
MD-354

Movement Movement
Episodes
Time
-

Movement
Distance
-

Vertical
Entries
-

Margin
Margin
Distance Time
-

Center
Distance
-

Center
Time
-

Center
Entries
-

Ondansetron

-

-

-

-

-

-

-

-

-

SR 57227A

-

-

-

-

-

-

-

-

↑

(+)Amph

↓

↑

↑

-

↑

-

-

-

-

+ MD-354

-

-

-

-

-

-

-

-

-

+ Ondan

-

-

-

-

↓

↓

↑

-

-

+ SR 57227A

↓

↑

↑

-

↑

-

-

-

-

(+)Meth

↓

↑

↑

↑

↑

-

-

-

↑

-

-

-

-

-

-

-

-

-

-

↑

↑

↑

↑

-

↓

-

-

-

↓

↓

↓

↓

-

↓

-

↓

↓

↑

↑

↑

↑

↑

↓

↓

-

+ MD-354

↓

↑

-

↑

-

-

↑

-

↑

+ Ondan

↓

-

-

-

↓

-

-

-

↑

+ SR 57227A

↓

↑

-

-

-

-

-

-

↑

+ MD-354
DOM
+ MD-354
Cocaine

a.

The “-” symbol indicates no change in effect compared to control, the “↑” symbol indicates an increase in effect versus

control, and the “↓” indicates a decrease in effect versus control. See text for a more detailed description and discussion of the
effects.

that which was found in the literature. Ramamoorthy et al. published a paper discussing
the antidepressant potential of the 5-HT3 receptor antagonist ondansetron (19).137 In this
study, locomotor activity was characterized as “locomotor scores”, analyzing various
doses of ondansetron (0.005-1000 μg/kg).137 For the entire dose range, ondansetron
produced saline-like effects in mice.137 Analysis of SR 57227A, when administered
alone, also resulted in saline-like effects, with the exception of center entries (Table 5);
this effect was only statistically significant when analyzed using the t-test instead of a
one-way ANOVA which was employed for testing the significance of other parameters.
The saline-like effect of SR 57227A is consistent with literature findings. Yoo et al.
analyzed the effect of SR 57227A (28) on locomotor activity and showed that SR
57227A did not produce locomotor stimulation when administered alone on the stimulant
parameter of distance traveled (movement distance).138 For all three 5-HT3 receptor
ligands, the results observed in the present investigation are consistent with literature
findings, even though not exactly the same types of parameters were measured. The 5HT3 receptor ligands are considered to not display any effect on mouse locomotor
activity when administered alone.
For each drug of abuse, varying doses were administered in order to determine an
effective dose of each drug. An effective dose of (+)amphetamine (2) was determined to
be 3.0 mg/kg as this dose (as well as a 6.0 mg/kg dose) increased the effect on the
common stimulant parameters of movement time and movement distance, while
decreasing movement episodes. Movement episodes are counted as one movement
episode being equivalent to the entirety of the movement between the initial start until the
110
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rodent stops. Therefore, if the mouse is continuously walking, movement time and
distance would increase, whereas movement episodes would decrease. The effect on
margin distance was also potentiated by 3.0 and 6.0 mg/kg doses of (+)amphetamine (2),
suggesting that the activity of the rodent was not only stimulated by (+)amphetamine, but
the rodent also began to display anxiogenic-like behavior. Mcgeehan et al. showed that
the locomotor activity parameter average distance traveled was significantly increased
following administration of 3.0 and 5.0 mg/kg doses of (+)amphetamine versus saline.139
Data from Glennon et al. further support this idea as locomotor activity (measured as
interruptions of photocell beam breaks) at even lower doses (1.0 mg/kg doses) of racemic
amphetamine injected i.p. increased locomotion in mice.140 However, doses of 0.3 mg/kg
produced saline-like effects.140 It is important to note, although Glennon’s study was
conducted using racemic amphetamine instead of one isomer, such as (+)amphetamine
(2) used in the current study, the use of a different type of locomotor activity apparatus
might account for the lower effective dose observed in the Glennon studies.140 Bushnell
also reported on the dose-dependent stimulant response of (+)amphetamine (0.3 to 10
mg/kg i.p.) on locomotor activity in mice;141 the findings of the present investigation
were consistent with the literature findings. It is important to note that an immense
amount of research has been published (thousands of papers) on dose response curves of
all four drugs ((+)amphetamine, (+)methamphetamine, DOM, and cocaine) in locomotor
activity assays using both mice and rats. Since this literature is so exhaustive, only a few
references have been cited. But, in general where literature data are available, they are
not inconsistent with the present findings.
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With many drugs of abuse, dose-response studies can be conducted to
demonstrate how increasing doses have an effect on particular parameters, such as
increasing movement distance with increasing doses of (+)amphetamine (2). Eventually,
however, a threshold is reached, where the dose of administered drug results in
stereotypy. In dose response curves this is often observed as either a plateau or even a
decrease in effect, creating an inverted U-shaped curve.126
Since MD-354 (42) is a 5-HT3 receptor partial agonist, it has the potential to
behave as either an agonist or an antagonist, and could possibly potentiate or antagonize
the effect of (+)amphetamine (2) when administered in combination by indirectly
influencing dopamine levels.

Therefore, both an effective dose (3.0 mg/kg) and

moderate dose (2.0 mg/kg) of (+)amphetamine (2) were used in combination with MD354 (42), in case MD-354 was to potentiate the effect of (+)amphetamine to the point of
stereotypy. Drug discrimination studies in rats have been conducted using similar dose
combinations of (+)amphetamine and MD-354; data showed MD-354 enhances the
stimulus effects of moderate doses of (+)ampethamine.142 Although there is a difference
in species and type of study conducted, the results support the notion that MD-354 can
potentiate a behavioral action of (+)amphetamine. However, in the present investigation,
neither dose combination resulted in potentiation or antagonism of the (+)amphetamine
(2) effect when compared to the effect of the stimulant administered alone. These results
were observed both with stimulant and non-stimulant parameters throughout the entirety
of the experiment.
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For comparison, an effective dose of (+)amphetamine (2) (3.0 mg/kg) was
administered in combination with the 5-HT3 receptor antagonist ondansetron (19).
Costall et al. indicated that the 5-HT3 receptor antagonist GR38032F (known as
ondansetron) inhibited hyperlocomotion (measured as counts) induced by intraaccumbens injections in rats.131

However in the present investigation, the 5-HT3

receptor antagonist ondansetron did not behave in a similar manner when administered in
combination with (+)amphetamine. Similar to the results observed with a combination
of MD-354 (42) and (+)amphetamine, ondansetron (19) neither potentiated nor
antagonized the stimulant effect of (+)amphetamine (2) compared to (+)amphetamine
administered alone. This effect was observed throughout the entirety of the experiment
for all stimulant parameters. However, a 1.0 mg/kg dose of ondansetron was able to
potentiate the effect of (+)amphetamine on the parameter center distance; that is,
ondansetron in combination with (+)amphetamine displayed an anxiolytic-like effect. The
difference in effect between the present investigation and that observed by Costall et
al.131 could be due to the difference in species, route of administration, and method of
determining locomotor activity. With the exception of this non-stimulant parameter
(center distance), it was concluded that in combination with (+)amphetamine (2), MD354 (42) is either behaving similar to a 5-HT3 receptor antagonist, or MD-354 is devoid
of action. Since the effects of the combination of MD-354 and (+)amphetamine on
locomotor activity parameters were similar to those observed with the combination of
ondansetron and (+)amphetamine, the conclusion that MD-354 is behaving in a similar
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manner to a 5-HT3 receptor antagonist is supported. However, the lack of potentiation or
antagonism of effect could also suggest MD-354 is devoid of action.
Combination of an effective dose of (+)amphetamine (2) with the 5-HT3 receptor
agonist SR 57227A (28) was examined. Whereas neither MD-354 (42) nor ondansetron
(19) altered the effect of (+)amphetamine (2) when administered in combination, SR
57227A (28) influenced the effect of a moderate dose of (+)amphetamine (2.0 mg/kg). A
moderate dose of (+)amphetamine was used instead of the effective dose in case the 5HT3 receptor agonist potentiated the stimulant effect of (+)amphetamine (2) to the point
of stereotypy.

The four parameters that were affected by administration of

(+)amphetamine (2) alone at a 3.0 mg/kg dose were also affected when (+)amphetamine
was administered in combination with SR 57227A (28). The combination of SR 57227A
(3.0 and 10 mg/kg doses) with (+)amphetamine potentiated the effect (+)amphetamine on
movement episodes (i.e., the number of movement episodes was decreased).

This

potentiation was more significant at the 3.0 mg/kg SR 57227A dose than the 10 mg/kg
dose. The combination of SR 57227A (28) with (+)amphetamine (2) also potentiated the
effect of (+)amphetamine on the stimulant parameters of movement time and movement
distance, as well as the non-stimulant parameter margin distance. This potentiation was
observed as an inverted U-shaped curve as the 3.0 mg/kg SR 57227A dose was the only
one that potentiated (+)amphetamine’s actions on all three parameters. For the other
parameters, vertical entries, margin time, center distance, center time, and center entries,
the combination of (+)amphetamine (2) with SR 57227A (28) behaved similarly to

(+)amphetamine when administered alone.
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Analysis of these results showed that

(+)amphetamine when administered alone produced a saline-like effect.
Results from combinations of (+)amphetamine (2) (3.0 mg/kg) with varying doses
of the 5-HT3 receptor antagonist ondansetron (19) indicated that the combination behaved
similarly to the results observed with (+)amphetamine and MD-354. The 5-HT3 receptor
agonist SR 57227A (28) behaved differently than either MD-354 (42) or ondansetron
(19) when administered in combination with (+)amphetamine (2). That is, SR 57227A
potentiated certain aspects of (+)amphetamine-induced locomotor stimulation, whereas
both MD-354 and ondansetron in combination with (+)amphetamine produced
(+)amphetamine-like effects. Hence, two conclusions are possible. Either MD-354 lacks
sufficient agonist potential to mimic the actions of SR-57227A, or too little MD-354 is
penetrating the BBB to reach its central sites of action, as drug discrimination studies
suggest that MD-354 is centrally acting;142 however, peripheral effects cannot be
excluded.
(+)Methamphetamine (3), a psychomotor stimulant structurally similar to
(+)amphetamine, was also tested in locomotor activity assays. Literature states that
(+)methamphetamine is a more potent central stimulant than (+)amphetamine (2);16
similar central stimulant effects should be evident at lower doses.

This idea was

supported as stimulant measures were increased at a 1.5 mg/kg dose of
(+)methamphetamine as compared to 3.0 mg/kg dose of (+)amphetamine. Doses of
(+)methamphetamine (3) increased movement time and movement distance while
suppressing movement episodes; this was similar to the results observed following
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administration of an effective dose of (+)amphetamine (2) alone. These effects also
created an inverted U-shaped curve as doses of 1.5 mg/kg increased stimulant parameters,
where a dose of 10 mg/kg had less of an effect; in some cases, no effect was observed.
Not only did (+)methamphetamine (3) potentiate the effect on stimulant parameters, but
lower doses (as low as 0.3 mg/kg) somewhat potentiated the three key stimulant
parameters (movement episodes, movement distance, and movement time) as well as
vertical entries, margin distance, and center entries after the first 15 min of the
experiment. Glennon et al. analyzed racemic methamphetamine in similar male ICR
mice and also observed an increase in locomotion (measured as interruptions of photocell
beams) at 1.0 mg/kg and above, whereas a 0.3 mg/kg dose of racemic methamphetamine
produced a saline-like effect.140 Once again, variances in effective dosage amounts could
be due to the use of racemic methamphetamine (3) as compared to its more potent
isomer.
In the present investigation, center entries was the only parameter increased by
(+)methamphetamine (3) that was not affected by (+)amphetamine (2), suggesting that
(+)methamphetamine is behaving more in an anxiolytic nature than (+)amphetamine.
However, both (+)methamphetamine and (+)amphetamine, at all doses administered,
produced saline-like effects on margin time, center distance, and center time.
Studies with 1.5 and 3.0 mg/kg doses of (+)methamphetamine (3) in combination
with varying doses of MD-354 (42) were conducted to determine if MD-354 was
behaving similarly to (+)amphetamine in combination with a structurally similar
psychomotor stimulant. For all combinations, MD-354 (42) plus (+)methamphetamine
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(3) produced results similar to those observed following administration of
(+)methamphetamine alone; this was observed for all nine parameters analyzed for the
entire duration of the experiment. Data from the combination of MD-354 (42) and
(+)methamphetamine (3) paralleled the results observed with combinations of MD-354
and (+)amphetamine (2). Apparently, the effect of MD-354 on the motor actions of
(+)methamphetamine and (+)amphetamine are similar.
DOM (10), a non-stimulant phenylalkylamine structurally similar to amphetamine
was used as a control. Supposedly lacking significant central stimulant properties, DOM
was not expected to influence “stimulant” measures of activity. However, it has been
previously shown that hallucinogens can produce both a stimulant effect in locomotor
activity assays as well as stimulus generalization; stimulus effects can be block by
serotonin antagonists.54
Results of the present investigation showed that DOM (10) at a low dose (0.3
mg/kg) significantly increased vertical entries. This is an activity measure that was not
affected by administration of either the psychomotor stimulant (+)amphetamine (2) or
(+)methamphetamine (3).

Also, DOM doses did not have an effect on movement

episodes, which was decreased by varying doses of psychomotor stimulants. This
increase in vertical entries, as well as no effect on movement episodes differentiates
DOM from the psychomotor stimulants. Other parameters affected by the administration
of DOM (10) included movement time, movement distance, and margin distance
suggesting the drug displayed some stimulant activity, which is consistent with literature
that states that low doses of DOM may produce stimulant effects.3 Yamamoto and Ueki
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analyzed the effect of DOM on locomotor activity in mice, and observed increases in
locomotor activity at 0.5 -1.0 mg/kg doses injected i.p.3 However, at 0.1 mg/kg, head
twitches, a hallucinogenic parameter was increased.3 Data observed in the present
investigation is consistent with Yamamoto and Ueki’s3 results, although the present study
did not analyze head twitches, but rearing as a hallucinogenic parameter.
By increasing vertical entries, the animal is in motion more, which in turn will
increase the amount of time the animal is in motion (i.e., movement time). Also, when
animals display rearing behavior, it is usually around the margins of the chamber, as the
mice look as if they are trying to climb out of the chamber; this can increase both margin
distance, margin time, and movement distance. Therefore, as vertical entries increase, it
is not uncommon for movement time, movement distance, margin distance, or margin
time to also increase. Further analysis of the effects of varying doses of the hallucinogen
DOM (10) showed results similar to those observed following administration of
(+)amphetamine (2) and (+)methamphetamine (3) (i.e., no effect), as DOM produced
saline-like effects for margin time, center distance, center time, and center entries.
Results of combination studies of an effective dose of DOM (10) (0.3 mg/kg) with
MD-354 (42) differed from those observed from combination of MD-354 with
(+)amphetamine (2) and (+)methamphetamine (3).

With both phenylalkylamine

stimulants, combination of MD-354 with (+)amphetamine or (+)methamphetamine
produced effects similar to the stimulant when administered alone.

However, in

combination with DOM (10), MD-354 (42) antagonized stimulant parameters as well as
other parameters analyzed. In particular, DOM (10) is a hallucinogen; vertical entries
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should be increased,
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which was observed with DOM administered alone as well as in

combination with MD-354. However, in combination with MD-354 (42), the effect of
DOM (10) on vertical entries, as well as movement time, movement distance, margin
distance, center distance and center entries were all completely blocked, resulting in a
saline-like effect. The only parameters not affected by this combination were movement
episodes, margin time, and center time, which were saline-like when DOM was
administered alone. Literature has shown that 5-HT2 antagonists block the stimulus
effect of DOM,54 therefore, similar results could be observed with a 5-HT3 partial agonist.
Cocaine (1) was evaluated as a non-phenylalkylamine stimulant that has a
different mechanism of action than (+)amphetamine or (+)methamphetamine, to
determine if MD-354 (42) behaves similarly or differently in combination than with
phenylalkylamine stimulants. Administration of varying doses of cocaine (1) indicated
that the stimulant significantly increased the effect on the same four parameters increased
by (+)amphetamine (2) and (+)methamphetamine (3). These four parameters, movement
episodes, movement time, movement distance, and margin distance, were significantly
increased at doses 10 mg/kg and 30 mg/kg; stereotypy was not observed at the high (30
mg/kg) dose. The present results are consistent with literature data as Mcgeehan et al.
showed that the average distance traveled was significantly increased following doses of
15 and 30 mg/kg of cocaine (1).139 Cocaine produced a saline-like effect on total vertical
entries, total margin time, total center distance, total center time, and total center entries
which coincides with the data found in both the (+)amphetamine (2) and
(+)methamphetamine (3) studies. This indicates that all three psychomotor stimulants are
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producing similar locomotor effects, regardless of their differences in mechanism of
action, since the overall effect is an increase in synaptic dopamine levels.
Studies were conducted to determine if MD-354 (42) behaved similar in
combination with cocaine (1) to combination with (+)amphetamine (2). An effective
dose of cocaine (10 mg/kg) was used in combination with the 5-HT3 receptor partial
agonist MD-354 (42). Potentiation of the effect of cocaine administered alone was
observed when in combination with MD-354 for several parameters: movement episodes,
movement time, vertical entries, center distance, and center entries (at various time
intervals). A decrease in movement episodes and an increase in movement time and
vertical entries was observed at all doses of MD-354 (42) in combination with cocaine
(1). Center distance and center entries were only affected at a higher dose of MD-354.
These results were observed at different time intervals. Analysis of the overall effect of
the combination indicated that MD-354 potentiated the effect of cocaine on center entries
at a 6.0 mg/kg dose. These results differed from those observed with a combination of
MD-354 (42) and (+)amphetamine (2), as the combination with MD-354 produced effects
similar to those observed with (+)amphetamine alone.
Combination of the same dose of cocaine (1) (10 mg/kg) with the 5-HT3 receptor
antagonist ondansetron (19) displayed results similar to the combination of MD-354 (42)
and cocaine. The effect of cocaine was potentiated in combination with ondansetron (19)
for movement episodes (i.e., movement episodes decreased). The effect of cocaine was
also potentiated in combination with ondansetron for center entries, whereas ondansetron
decreased the effect of cocaine on margin distance.

The effect of cocaine (1)
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administered alone increases margin distance; however in combination with ondansetron,
the effect was blocked, resulting in a saline-like effect. The effect of ondansetron on
cocaine varied between different time intervals. However, analysis of the total effect of
the combination of drugs on the nine parameters showed that only center entries were
affected at 0.5 and 1.0 mg/kg doses of ondansetron (potentiated the effect of cocaine).
Several different 5-HT3 receptor antagonists (i.e., zacopride, tropisetron,
bemesetron, and ondansetron) have been studied in combination with cocaine, usually
resulting in attenuation of the effect of cocaine. Le et al. analyzed locomotor activity
counts in male DBA/2N mice,143 which differed from the ICR strain of mice used in the
present studies. Low doses of ondansetron (19), 0.001, 0.01, and 0.1 mg/kg were
administered s.c. in combination with cocaine (1) to yield slightly different results from
those observed in the present investigation, as the combination of ondansetron did not
potentiate or antagonize the stimulant effects of cocaine.143 The differences in the results
could be due to the type of rodent used as well as the route of administration. King et al.
indicated that varying doses of ondansetron (1.0 -16 mg/kg i.p.) attenuated the effect of
cocaine (15 mg/kg i.p.) in male Sprague Dawley rats.130 Locomotion was measured using
the Ellinwood and Balster rating scale.130

Svingos and Hitzemann conducted a study

analyzing the effect of zacopride, tropisetron, and bemesetron on an effective (10 mg/kg)
dose of cocaine.129 All three 5-HT3 receptor antagonists (injected i.p.) attenuated the
effect of cocaine in rats when analyzing locomotion (measured as the number of quadrant
crossovers).129 Further support for attenuation of the effect of cocaine by 5-HT3 receptor
antagonists was determined by Reith.132 The effect of tropisetron (injected s.c), as well
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as zacopride (injected i.p.), in combination with a 25 mg/kg dose of cocaine were
determined; combination resulted in attenuation of locomotor counts in male
C57BL/6ByJ mice.132

In the present study, ondansetron behaved similarly to the

different 5-HT3 receptor antagonists discussed by attenuating the effect of cocaine on
margin distance. However, other parameters were potentiated by the combination of
ondansetron with cocaine. The differences in attenuation of effect observed with several
5-HT3 receptor antagonists and the present study could be due to route of administration,
doses, difference in species, as well as the method used for determining locomotor
activity.
For the present study, a combination of cocaine (1) with ondansetron (19)
produced effects similar to those observed with combinations of cocaine and MD-354
(42). Analysis of data suggests that MD-354 is behaving similar to the 5-HT3 receptor
antagonist ondansetron when administered in combination with an effective dose of
cocaine (1). This is because combination studies of MD-354 and cocaine, as well as
ondansetron and cocaine, produced similar effects on cocaine. This is similar to the
results observed with MD-354 (42) in combination with (+)amphetamine (2), suggesting
that in combination with psychomotor stimulants, regardless of mechanism of action,
MD-354 either behaves similar to a 5-HT3 receptor antagonist or is devoid of action.
A combination study was conducted using the 5-HT3 receptor agonist SR 57227A
(28) with a 10 mg/kg dose of cocaine (1). The dosage was not altered for cocaine as in
the (+)amphetamine (2) study, as the cocaine dose-response curve suggested that there
was a large range of effective doses of cocaine before the threshold of stereotypy was
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reached. The results of the combination study showed that SR 57227A (28) potentiated
the stimulant effect of cocaine by decreasing movement episodes, and increasing
movement time and center entries at various time intervals; these same three parameters
were affected in a similar manner by the addition of MD-354 (42) to cocaine (1),
suggesting MD-354 is behaving like a 5-HT3 receptor agonist. However, analysis of the
results of the total effect showed that the only parameter affected by the combination was
center entries; SR 57227A potentiated the effect of cocaine on center entries when
analyzed using an un-paired t-test.
The results of the present study were further investigated as MD-354 (42) was
seemingly behaving as both a 5-HT3 receptor agonist and 5-HT3 receptor antagonist when
analyzing the total effect of each 5-HT3 receptor ligand in combination with cocaine:
analysis of all nine parameters showed that the 5-HT3 receptor ligands displayed no effect
on cocaine except with the parameter center entries. Since similar effects were observed
when analyzing total parameters, the effect of the combination of 5-HT3 receptor ligands
on cocaine were analyzed at different time intervals. Combination studies of MD-354
and cocaine, ondansetron and cocaine, and SR 57227A and cocaine all potentiated the
effect of cocaine on movement episodes and center entries. Since MD-354 is a 5-HT3
receptor partial agonist, it has the potential to behave as either/both an agonist and
antagonist.

It was concluded that in combination with cocaine (1), MD-354 (42)

behaved similarly to a 5-HT3 receptor agonist, based on the evidence provided by other
locomotor activity parameters analyzed.

Three parameters, movement episodes,

movement time, and center entries were potentiated by both ondansetron (19) and
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SR57227A (28), suggesting MD-354 (42) worked as both a 5-HT3 receptor agonist and a
5-HT3 receptor antagonist. Ondansetron (19) also antagonized the effect of cocaine (1)
on margin distance. This antagonism was distinct, and not observed in combination
studies of cocaine with MD-354 (42) or SR 57227A (28). By actually antagonizing the
effect instead of modulating the effect on margin distance, as compared to MD-354 and
SR 57227A studies, the antagonist is blocking effect of the drug. Since neither the 5-HT3
receptor partial agonist or 5-HT3 receptor full agonist display this or similar effects (i.e.,
attenuation of effect of cocaine on margin distance), it is supported that MD-354 (42) is
working through a 5-HT3 receptor agonist mechanism in combination with cocaine (1).
Table 5 summarizes the results of the locomotor activity studies conducted in the present
investigation.
For the three psychomotor stimulants ((+)amphetamine (2), (+)methamphetamine
(3), and cocaine (1)) margin distance was increased when the drug of abuse was
administered alone.

This could be a result of the drugs inducing anxiogenic-like

behavior. However, this could just be a result of stimulation. It is normal for rodents to
display anxiogenic-like activity, which is supported by the high values obtained for
margin distance and margin time as opposed to center distance and center time. When a
psychomotor stimulant was administered, the mice displayed increased locomotion. If
the mice are walking more following the administration of a stimulant, and generally tend
to walk around the margins, then it is likely the mice will walk more around the margins
when administered a stimulant.

The stimulants may be producing anxiogenic-like

behavior, but also could be displaying thigmotaxis in a stimulated manner.
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In conclusion MD-354 (42) may either behave as a 5-HT3 receptor antagonist in
combination with phenylalkylamine stimulants, or be devoid of action as it neither
potentiates

nor

antagonizes

(+)methamphetamine (3).

effective

doses

of

(+)amphetamine

(2)

nor

However, in combination with a non-phenylalkylamine

stimulant, that releases dopamine through a different mechanism of action, MD-354 (42)
might behave as a 5-HT3 receptor agonist, by potentiating several stimulant and nonstimulant parameters as seen with the 5-HT3 agonist SR 57227A. The differences in
mode of action of MD-354 may be a result of the mechanism of action of each stimulant
to release dopamine.
MD-354 is a 5-HT3 partial agonist with a low Log P value suggesting it does not
cross the BBB. However, drug discrimination studies, which can indicate whether or not
a drug acts centrally (i.e., crosses the BBB), have shown that MD-354 serves as a
discriminative stimulus11 and that MD-354 enhances the discriminative stimulus action of
(+)amphetamine in rats.143 Currently it is unknown whether MD-354 works peripherally.
Analysis of ex vivo studies indicated that the 5-HT3 receptor agonist, SR 57227A, crosses
the BBB and acts both centrally and peripherally.111 Since MD-354 neither potentiated
nor antagonized the stimulant effect of (+)amphetamine in the locomotor activity assay it
is not displaying a central effect, compared to the central acting 5-HT3 agonist which
potentiated the stimulant effect of (+)amphetamine. Although locomotor activity assays
are in vivo studies that analyze central effects, the possibility of a peripheral effect of
MD-354 can not be excluded.
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Comparison of MD-354 and (+)amphetamine with MD-354 and cocaine suggests
differences in mode of action, as MD-354 potentiated the effect of cocaine on various
parameters, at various time intervals. Similar effects were observed with SR 57227A
suggesting that in combination with a stimulant that has a different mechanism of action,
MD-354 may behave both centrally and peripherally.
In conclusion, in combination with phenylalkylamine stimulants, the 5-HT3
receptor partial agonist MD-354 may be devoid of action because it is not lipophilic
enough to cross the BBB, crosses the BBB, but at a dose too low to cause an effect if
MD-354 is a centrally acting agent, or is behaving similar to a 5-HT3 receptor antagonist.
However, in combination with a non-phenylalkylamine stimulant, MD-354 behaves
similar to SR 57227A which acts both centrally and peripherally.

B. Synthesis
1. Preparation of phenyl carbamate analogs of MD-354.
MD-354 (42) was prepared as previously described (Scheme 1).144
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Scheme 1. a. HCl/Et2O; b. NH2CN, EtOH, reflux; c. NH4NO3, H2O.

127
Several different methods were used to synthesize carbamate analogs of MD-354.
For the methyl carbamate analog 62, a one-pot synthesis by Khasanov145 was employed
(Scheme 2).
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Scheme 2. a. H2O, 45 °C; b. 40% NaOH, reflux, 4.5 h.

The first attempt to prepare the phenyl carbamate 53 was to follow the same
method used in the synthesis of the methyl carbamate 62 (Scheme 3).145 Calcium
cyanamide was allowed to react with phenyl chloroformate (63).

3-Chloroaniline

hydrochloride (60) was added to the filtrate and the pH was adjusted to 4. The precipitate
was collected by suction filtration and recrystallized from anhydrous MeOH.

1

H NMR

spectral analysis indicated that the product was not the desired carbamate 53, but a dimer
of 3-chloroaniline, N,N’-bis(3-chlorophenyl)urea (64). Urea 64 is a known146 compound.
Comparison of the melting point of 64 with literature data supported this
characterization.146 The structure of 64 was also supported by microanalysis for C, H,
and N.
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Scheme 3. a. H2O, 45 °C, 30 min; b. 40% NaOH, reflux overnight.

This same procedure was followed using 4-chlorophenyl chloroformate (65) and
4-methoxyphenyl chloroformate (66) (Scheme 4). In both instances, the resultant white
precipitate was also identified as the 3-chloroaniline dimer 64.
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Scheme 4. a. H2O, 45 °C, 30 min; b. 40% NaOH, reflux overnight.
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In general, there are numerous methods available to synthesize ureas. For the
most part, ureas are extremely stable, and most of the routes of synthesis are very clean
and easy to perform.147 Interestingly, one of the common methods to synthesize ureas
includes carbamates as starting material. Liu et al. reported a two-step synthesis which
used a chloroformate and an amine to obtain a carbamate, followed by the addition of an
amine to form a urea.147 This reaction could be conducted both in organic and aqueous
solvents. Liu et al. also stated that the reaction of isocyanates with amines can also
produce ureas under mild conditions.147
Therefore, with the reaction conditions used in Scheme 3 and Scheme 4, the
desired carbamate may have been synthesized, but was quickly converted to the urea, as
urea may be a more stable compound than the phenyl carbamate 53. Further analysis of
the reaction mechanism showed that several side products other than the desired phenyl
carbamate can be obtained (i.e., isocyanate derivative).

If an isocyanate had been

formed, it too could have been converted into the urea in the presence of excess amine.
Since the reaction yielded several products (tlc), which could include both the isocyanate
(and infrared analysis of the crude reaction mixture showed the possible formation of an
isocyanate intermediate as evidenced by a band at 2359 cm-1), the desired carbamate, and
unreacted amine, conditions employed during purification might have resulted simply in
the isolation of one of these products, the urea 64.
Another attempt was made to synthesize the phenyl carbamate analog of MD-354
using a procedure by Naiman (Scheme 5).148 In this procedure, MD-354 (free base; 42)
was added to a solution of triethylamine and dry THF. A THF solution of phenyl
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chloroformate (63) was added to the reaction mixture and the reaction was monitored by
tlc. The triethylamine hydrochloride precipitate (mp = 261 °C)149 was removed by
filtration and the solvent was evaporated to obtain an oil which was subjected to flash
chromatography. Three products were obtained: two were unstable and decomposed
rapidly upon standing as evidenced by tlc. A third product was recrystallized from
anhydrous MeOH. 1H NMR spectral analysis of the latter product indicated the presence
of three aliphatic protons (signal at δ = 3.60 ppm) that corresponded to the methyl group
of methyl carbamate 62. Melting point and tlc analysis further supported this conclusion:
Rf = 0.35 (3:2 hexane:EtOAc).
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Scheme 5. a. Et3N, THF; crystallized from MeOH.

Looking back at the previous reaction, tlc analysis indicated that a significant
amount of starting material was still present after the 15-min reaction time. Therefore,
the reaction was repeated (Scheme 5), but allowed to continue until all the starting
material was consumed (17 h). Several additional products were formed (tlc). The
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resultant oil was crystallized from anhydrous MeOH several times to yield a white solid.
1

H NMR spectral analysis and melting point indicated that the methyl carbamate 62 was

obtained, again with three aliphatic proton signals present in the 1H NMR spectrum.
Based on this information, it was thought that the desired product could more easily be
isolated using a shorter reaction time; this was employed in future trials. However,
higher yield of the methyl carbamate 62 was obtained during purification using
recrystallization methods (17%) as opposed to flash chromatography (3%).
Synthesis of the methyl carbamate 62 from phenyl chloroformate 63 indicated
that methanolysis might be occurring.

Two separate purification techniques were

employed to determine if heat was necessary for this to occur. The reaction was repeated
and the resultant oil was divided into two batches. One batch crystallized upon addition
of hot MeOH, which yielded the methyl carbamate. The other batch was subjected to
MeOH at room temperature. A solid material precipitated from the addition of MeOH,
but could not be purified. This supported the conclusion that heat is necessary for
methanolysis to occur because methyl carbamate 62 was not isolated from the latter
reaction.
The next attempt to synthesize the phenyl carbamate analog of MD-354 used the
procedure of Gotz and Zeeh150 (Scheme 6). This method consisted of adding cyanamide
to water while maintaining a pH of 7-8. Phenyl chloroformate (63) was added to the
reaction mixture, and was allowed to stir, followed by the addition of 3-chloroaniline
(59); pH was adjusted to 3. Basification of the filtrate resulted in immediate precipitation
of a white solid (NaCl; mp > 300 ˚C). A second product was present on tlc which was
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determined to be phenol (67); Rf = 0.83 (3:2 hexane:EtOAc). Synthesis of phenol and
NaCl prevented the reaction from proceeding to completion.
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+

Cl
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Cl

O

63
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Scheme 6. a. H2O, 50% NaOH, conc. HCl (pH 7-8), 45 °C, 1 h; b. conc. HCl (pH 3),
reflux, 45 min.

Further analysis of the literature suggested that commercially available phenyl
chloroformate is not very stable, and could be hydrolyzed to phenol or decompose in the
presence of water, heat, or air, all three of which were present in the previous attempts.151
Therefore, the reaction conditions for the previous reactions were modified. Using the
method of Khasanov145 (Scheme 7), acetone rather than water was used as solvent in the
first step of the reaction, and the reaction was conducted at room temperature instead of
at 45 °C. A calcium cyanamide/acetone mixture was added to phenyl chloroformate (63)
and the reaction mixture was allowed to stir. 3-Chloroaniline hydrochloride (60) was
added to the filtrate and stirring was continued; the pH was not changed. The solution
was evaporated under reduced pressure to yield a white solid. Recrystallization attempts
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were made with several solvents (i.e., ethyl acetate, acetonitrile, and acetone) with
acetone as the only solvent able to dissolve the product without heat. Once again, 1H
NMR spectral analysis suggested the product was not the desired phenyl carbamate 53.
Instead, 1H NMR and elemental microanalysis supported the conclusion that the product
obtained was the tetra-carbamate analog of MD-354 as its hydrochloride salt (i.e., 68).
This conclusion was further supported by the IR spectrum that showed a carbamate
peak(s) at 1586 cm-1.
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Scheme 7. a. acetone, rt, N2, 45 min; b. rt, N2, 4 h.

The formation of tetra-carbamate 68 could be due to the fact that the reaction was
not run in a 1:1 ratio of starting materials. Instead, a 2:1 carbamate:amine ratio was used,
which could result in a dicarbamate product.

When running the reaction, it was

extremely difficult to add the CaCN2/acetone mixture to phenyl chloroformate (63)
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because calcium cyanamide was not soluble in the solvent. Therefore, it is likely that not
all of the calcium cyanamide was added, causing even more of an excess of phenyl
chloroformate. The basicity of the amines in the presence of excess acid chloride could
result in multiple couplings, creating tetra-carbamate 68.
Another attempt to synthesize the phenyl carbamate analog of MD-354 was made
using protecting groups (Scheme 8).152,153 In this method, 1H-pyrazole-1-carboxamide
hydrochloride (69) was allowed to stir with diisopropylethylamine and CH2Cl2.

A

solution of phenyl chloroformate (63) and CH2Cl2 was added to the mixture. Once the
reaction was complete (tlc), the product was extracted using aqueous sodium bicarbonate
and brine. The extract was dried (sodium sulfate), filtered, and solvent was evaporated
under reduced pressure to yield a white, fluffy solid, the phenyl ester 70 of the pyrazole.
The product was characterized by 1H NMR spectral analysis and elemental analysis.
The ester 70 and 3-chloroaniline hydrochloride (60) were allowed to stir in
refluxing diisopropylethylamine (DIEA). Once all starting materials were consumed
(tlc), the solvent was evaporated under reduced pressure and the resultant crude product
was isolated using column chromatography: 3:2 hexane:EtOAc. The crude product was
recrystallized from acetone to yield the urea 64.
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Scheme 8. a. DIEA, DCM, rt, 2 h; b. DIEA, reflux overnight.

Once again, ureas are easily synthesized by the addition of amine to carbamates.
Since characterization of intermediate 70 indicated that the desired carbamate had been
formed, then the phenyl carbamate 53 should be synthesized. However, the more stable
urea was isolated. The literature states that the reaction of protected pyrazole with simple
primary amines is rapid and needs to be monitored closely.153 However, reduction in
nucleophilicity drastically increased reaction time sometimes preventing the reaction
from proceeding (e.g. the amine p-nitroaniline suppressed reaction time completely).153
Even though m-chloroaniline is more nucleophilic than p-nitroaniline,154 the electronwithdrawing group may be strong enough to suppress the reaction, resulting in the urea
64 instead of the desired phenyl carbamate 53.
Based on previous synthetic attempts to prepare phenyl carbamate 53 that
indicated the occurrence of methanolysis, the concept of alcoholysis was analyzed. The
theory was put to use with the simple reaction of acid chloride and amine in dry THF to
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synthesize a carbamate. Different bulky alcohols (i.e, isoporopanol and n-butanol) would
then be used to isolate bulky carbamates, such as the isopropyl carbamate or n-butyl
carbamate. A THF solution of phenyl chloroformate (63) was added to a solution of MD354 (free base; 42), triethylamine, and dry THF (Scheme 9).

The triethylamine

hydrochloride was removed by filtration and the filtrate was evaporated under reduced
pressure to yield a yellow oil. The oil was divided into two separate batches; isopropanol
was added to one and n-butanol was added to the other at room temperature. The
precipitates from each batch were collected and washed with Et2O. It was expected that
one reaction would yield the isopropyl carbamate whereas the other would provide the
butyl counterpart. Comparison of the two products indicated the same material was
formed in both cases (melting point, tlc, and 1H NMR spectral analysis).

1

H NMR

spectral analysis and elemental analysis supported the conclusion that the structure was
that of the desired phenyl carbamate 53.
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63
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Scheme 9 . a. ET3N, THF, N2, 15 min; b. isopropanol; c. n-butanol
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The purpose of using the bulky alcohols in this reaction was to support the idea
that alcoholysis was occurring. However, synthesis of the phenyl carbamate 53 instead
of either the isopropyl carbamate or the butyl carbamate indicated that this was not the
case. Several factors may contribute to this. It was shown that for methanolysis to occur,
heat was necessary. However, at no point was heat used in the purification of the phenyl
carbamate 53 (Scheme 9). Therefore, alcoholysis may not have been able to occur since
heat was not present to hydrolyze the phenyl carbamate 53. Also, alcoholysis may have
been prevented due to the actual bulkiness of isopropanol and n-butanol. Since MeOH is
a much sterically smaller (less bulky, and/or more acidic) compound, it could attack the
phenyl carbamate 53 and convert it to the methyl carbamate 62. However, since the other
alcohols employed were bulkier, steric interactions due to the structure of the phenyl
carbamate 53, may have prevented the alcohols from attacking the compound, which in
turn prevented alcoholysis. Therefore, the phenyl carbamate 53 was isolated instead of
the isopropyl or butyl carbamates. Also, alcoholysis may not have occurred due to the
polarity of the bulky alcohols; the bulky alcohols are less polar and less acidic than
MeOH, therefore they are less reactive. The less polar nature of isopropanol and nbutanol as opposed to MeOH, may require more extreme conditions, such as the use of
heat, to allow alcoholysis to occur.
The stability of the final product was of concern since so many attempts showed it
to be unstable. Therefore, the final product was heated with H2O. Within 15 min, the
phenyl carbamate 53 began to hydrolyze and by 30 min there was no phenyl carbamate
present as evidenced by tlc. Analysis by tlc indicated that the phenyl carbamate 53 may
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have been hydrolyzed to its carbamic acid 71 which decarboxylated to form starting
material, m-chlorophenylguanidine (42, free base), Rf = 0.77 (MeOH) (Scheme 10). The
phenyl carbamate also hydrolyzed to MD-354 in room temperature H2O; hydrolysis
occurred at a slower rate than in refluxing H2O. It is important to note that heat and
water were not necessary to decompose the phenyl carbamate; in a separate reaction, the
product decomposed while in EtOAc in a sealed vial at room temperature. These data
support the idea that carbamate 53 is relatively unstable. Therefore, the carbamate was
not evaluated in animal studies, as it may hydrolyze or decompose too quickly to attain
any reliable results.

NH
HN

O
N
H

NH

NH

O
H

O

HN

N
H

HN

O

NH2

a
+ CO2
Cl

53

Cl

Cl

71

42 (Free base)

Scheme 10. a. H2O, reflux

The same procedure was applied to the synthesis of both the 4-chlorophenyl
carbamate 54 and the 4-methoxyphenyl carbamate 55. However, attempts at purification
were unsuccessful. Also, it was noted that the crude products were extremely unstable,
and decomposed in sealed vials (tlc). This lack of apparent product stability was the
basis for not continuing with the pharmacological aspects of this study.
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2. Preparation of a conformationally-constrained analog of MD-354.
2-Amino-6-chloroquinazoline hydrochloride (57) was synthesized using a general
method described by Grosso and Nichols (Scheme 11).155 Commercially available 5chloroisatoic anhydride (73) and S-methylisothiourea (72) were heated at reflux in 1,4dioxane. The resulting quinazolinone 74 was reduced with diborane in refluxing THF to
obtain the free base 57, which was converted to its hydrochloride salt using an HCl/ether
solution.
The progress and purity of each step of the reaction was monitored by tlc using
3:2 hexane:EtOAc as eluent.

1

H NMR spectroscopy of the final target indicated the

presence of two aliphatic proton signals at δ = 4.49 ppm that correspond to the methylene
group of 57 after the reduction of lactam 74. Similarly, the IR spectrum showed absence
of the lactam group at 1679 cm-1 seen in 74. The physicochemical properties of 57 were
compared with those of a sample previously synthesized in our laboratory but incorrectly
assigned structure 56.

Both compounds possessed identical melting points, Rf = 0.26

(H2O), IR, 1H NMR, and microanalytical properties.
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Scheme 11. a. 1,4-Dioxane, Na2CO3, reflux, overnight; b. BH3-THF, reflux, N2, 2.5 h; c.
HCl/Et2O, recrystallized from EtOH.

The conformationally-constrained analog of MD-354 (i.e., 57) was synthesized to
confirm the structure of a compound previously synthesized in our laboratories, and
whose structure may have been misassigned. Previously, it was believed that 2-amino-7chloroquinazoline hydrochloride (56) had been obtained; however, analysis of the
synthesis indicated that the position of the chloro group was in question. Therefore, two
reactions were performed using different starting materials, 5-chloroisatoic anhydride and
4-chloroisatoic anhydride, to yield the respective 6- and 7-chloroquinazolines. The 7chloro analog, 56, has been independently synthesized in our laboratory by an
unequivocal route and has been shown to be different in structure from that of 57 (Ownby
and Dukat, unpublished data as shown in Scheme 11).
1

H NMR spectral analysis indicated that the difference between the 6-chloro

quinazoline and the 7-chloroquinazoline was a shift of two aromatic hydrogen signals
upfield. These data were compared to the 1H NMR data of the previously reported
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compound, which supported the conclusion that the structure had been misassigned and
that the 2-amino-6-chloroquinazoline hydrochloride (57) had originally been synthesized.

C. Molecular Modeling
QSAR studies were conducted on 5-HT3 receptor agonists and partial agonists to
evaluate Dukat’s current working pharmacophore accounting for the binding of
arylguanidines and arylbiguanides at 5-HT3 receptors.14 Since many of the arylguanidine
and arylbiguanide ligands are meta-substituted, and because there are two meta-positions
(3 and 5), rotameric binding can occur. Therefore, constrained analogs were included to
better account for the possibility of rotameric binding.
An arginine fragment obtained from SYBYL was used to construct a model of
MD-354 (42), which served as the template for all of the arylguanidine analogs shown in
Table 6.

The crystal structure of m-chlorophenylbiguanide was obtained from the

Cambridge Database (Identification name FERDOW), and was used as a template to
construct the arylbiguanide analogs shown in Table 7.

Since there are two meta-

positions, selection of substitution was based on Ki values; meta-substituted analogs with
Ki values ≥700 nM were labeled as 5-substituted analogs, whereas those with Ki values
<700 nM were labeled as 3-substituted analogs. This classification was based on the
constrained analogs used in the model; the 5-chloroquinazoline bound with an affinity
>700 nM, therefore meta-substituents with higher affinity were placed in the 3-position.
Also, for analogs that were di- and tri-substituted, substitution positions were determined
based on binding affinity.

For example the 3,6-dichloro arylbiguanide analog was
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labeled as such, instead of 2,5-dichloro arylbiguanide, because the binding affinity was
less than 700 nM, which was consistent with monosubstituted 3-chloro analogs.

Table 6. Arylguanidine 5-HT3 receptor agonists/partial agonists and their respective
binding affinities used in the present QSAR studies.113,115
NH
HN
1

NH2
6
R
5

2
3
4

#

R=

pKi

#

R=

pKi

41

H

5.63

83

4-C2H5

6.11

42

3-Cl

7.49

43

3,4-fused phenyl 7.74

47

5-CF3

5.61

84

4-C6H5

8.15

75

5-OH

5.69

48

3,4-Cl

8.51

76

3-CN

6.91

51

3-CF3, 4-Cl

7.44

77

5-OCH3

5.80

85

4,5-OCH3

5.57

78

4-CH3

6.3

46

5-CH3

5.19

45

4-Cl

6.49

86

4-C(CH3)3

5.68

79

4-CF3

6.64

87

4-C6H5

5.60

80

4-OCH3

6.00

49

3,5-Cl

8.30

81

3-Cl, 5-OCH3 7.74

50

3,4,5-Cl

9.15

82

4-CH2C6H5

6.60
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Table 7. Arylbiguanide 5-HT3 receptor agonists/partial agonists and their respective
binding affinities used in the present QSAR studies.115
NH
HN
1

NH
N
H

NH2

6
R
5

2
3
4

#

R=

pKi

#

R=

pKi

29

H

5.92

89

3-Cl, 4-CH3

6.65

30

3-Cl

7.75

39

3,5-Cl

8.74

37

3,5,6-Cl

9.40

90

3,5-CF3

5.92

38

3,4-Cl

7.92

91

3,6-Cl

8.54

40

3,4,5-Cl

8.57

92

2,3-Cl

8.33

32

6-Cl

7.21

93

4,6-F

6.59

33

4-Cl

6.68

94

4-F

6.21

88

4-CH3

6.05

95

4-CF3

6.16

31

3,4-fused phenyl

7.85

The structures of 43 arylguanidines and arylbiguanides (with Ki values spanning a
10,000-fold range), including three constrained analogs (57, 58, and 96; Figure 58) were
constructed and minimized using Gasteiger Hückel algorithms. These 43 analogs were
used as a training set and aligned using a Least Squares Method: the Fit Atom function.
Alignment was based on three common points of the structure of MD-354 (42): the aryl
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3-position, the aryl 5-position, and the carbon atom of the guanidine moiety (as shown in
Figure 59).
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N

NH2
N

NH

NH

Cl

Cl

Cl

57

58

96

pKi = 7.10

pKi = 6.13

pKi = 6.14

Figure 58. Constrained analogs and their respective binding affinities used in further
evaluation of the 5-HT3 receptor working pharmacophore model.13,135

CoMFA studies were conducted on the training set of 43 arylguanidine and
arylbiguanide derivatives. Analysis indicated there was a 63% steric contribution and a
37% electrostatic contribution (r2 = 0.681, q2 = 0.693) with 5 as the optimal number of
components.

Since the predictability factor (q2) was above 0.60, the model was

considered to be acceptable and could be used to predict binding affinities of
arylguanidine or arylbiguanide analogs. In general, models with r2 values above 0.60
have good predictability, however, the closer to 1 the r2 value, the better the
predictability.
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Figure 59. A) Three points used for alignment of all 43 training-set compounds. B) All
43 compounds aligned in CoMFA.

These results differ from those observed in the previous pharmacophore model as
the previous model only used a total of 33 compounds instead of 43 as employed in the
current investigation.113 In the previous model, similar compounds were used for both
arylguanidines and arylbiguanides; mono-, di-, and tri-substituted compounds, as well as
the 2-napthyl analogs. However, the previous model did not include bulky substituents at
the 4-position or any of the constrained analogs.113 It did, however, include substitution
within the guanidine moiety, which is not included in the current investigation.113 The
same three points, aryl 3-position, aryl 5-position, and the cationic carbon attached in the
guanidine moiety were used for alignment.113

However, with the previous model,

CoMFA studies resulted in r2 = 0.851 and q2 = 0.584.113
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The difference in predictability of the model generated in the present studies
versus that of the previous model not only could be due to the addition of constrained
analogs to the training set, but also the function of these constrained analogs. Currently,
is not known whether these constrained analogs behave in an agonist or antagonist
manner. 5-HT3 receptor agonists and antagonists may bind to the receptor in a different
manner.

If this is the case, and both models are supposed to be representative of

arylguanidine and arylbiguanide 5-HT3 receptor agonists and partial agonists, the addition
of ligands with unknown functionality may decrease the predictability of the model.
Validation of the model was completed using a test set of five (arbitrarily
selected) compounds, whose known pKi values were compared to the pharmacophore
model’s predicted values (Figure 60). The predictability of the validation set was high as
some affinities were predicted within 2- to 3-fold.
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Figure 60. Predicted pKi and Ki values of five arbitrarily selected test-set compounds
from the CoMFA model compared to their known113,115 pKi and Ki values.

Figure 61 displays the region in the pharmacophore model where electrostatic
interactions are favorable versus unfavorable. There was only a small area near the aryl
5- and aryl 6-positions where negatively charged substituents were favored. The aryl 3and aryl 4-positions possessed a large region favoring positively charged substituents.
These interactions were also favored around the guanidine moiety.
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Figure 61. CoMFA results analyzing only electrostatic interactions (n = 43). Blue is a
region were positively charged substituents are favored, whereas red represents regions
where negatively charged substituents are favored. MD-354 (42) is displayed in the
model.

CoMFA results also displayed regions where steric interactions are favorable
versus unfavorable (Figure 62). A small area of bulk tolerance was observed near the
aryl 3-position. However, this area did not extend too far away from the aromatic region.
It was observed that steric interactions were unfavorable to a large extent at the aryl 4position. Therefore, bulky substituents are not favored and, in fact, compounds display
lower binding affinities when they bear such substituents near this region.
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Figure 62. CoMFA results analyzing regions of steric tolerance (n = 43). Green areas are
regions where bulky groups are favored and yellow represents areas where bulky
substituents are unfavored. MD-354 (42) is the compound represented in the model.

Based on the CoMFA studies, there are more regions of favorable electrostatic
interactions than favored steric interaction.

This could be due to the number of

arylguanidines and arylbiguanides that had variable electrostatic substituents versus the
amount of sterically hindered 5-HT3 receptor agonists/partial agonists employed in the
training set. Figure 63 displays the full results of the CoMFA study, which differ from
Dukat’s pharmacophore model as the previous model provided more information about
substitution within and around the guanidine moiety. However, that model included
analogs with substitution within the guanidine moiety as opposed to the present model
that did not include these types of analogs.
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Figure 63. CoMFA results including favorable and unfavorable regions of steric and
electrostatic interactions (n = 43). Blue areas are regions where positively charged
substituents are favored, whereas red areas are regions where negatively charged
substituents are favored. Green areas are regions where bulky groups are favored and
yellow areas are regions where bulky substituents are unfavored. MD-354 (42) is
compound displayed in the model.
This model differs from results of the previous CoMFA model as bulky
substitutents are favored close

to the aryl 3- and aryl 5-positions, whereas bulky

substituents are unfavored around the majority of the aryl-positions (further out from the
aryl 3- and aryl 5-positions) and around the guanidine moiety.113 The present model
suggests that bulky substituents are favored near the aryl 3-position, and disfavored
around the aryl 4-position, however, this is the only information the present investigation

provides relating favorable and unfavorable regions or steric bulk.
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Therefore, the

present investigation is not as informative as the previous model on the location of where
regions of bulk are preferred versus unfavorable regions.
Also, the present investigation displays large regions where electrostatic
interactions are favored (i.e., positively charged substituents improve affinity). This is
observed near the aryl 3-, aryl 4-, and aryl 5-positions, as well as within the guanidine
moiety. The previous model also displays favorable electrostatic interactions within the
guanidine moiety, as well as near the aryl 5-position, however these interactions are
unfavored near the aryl 3-position.113

This could be due to assignment of meta-

substituents to the 3- versus 5-position based on binding affinity relative to the
constrained analogs. Once again, constrained analogs were not present in the previous
study.
CoMSIA studies can provide information on steric, electrostatic, hydrophobic, Hbond donor, and H-bond acceptor regions. All five aspects were analyzed in the present
study (n = 43), however the r2 values were low (r2 < 0.50) on all parameters analyzed
except hydrophobic interactions. With this parameter, slightly better predictability was
observed (r2 = 0.51, q2 = 0.50), as opposed to H-bond donor/acceptor, electrostatic, and
steric parameters. Although this predictability is not too reliable, as r2 is not greater than
0.60, it still can be used to give some insight into regions where hydrophobic interactions
are favorable versus unfavorable (Figure 64).
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Figure 64. CoMSIA results showing regions of hydrophobic interaction (n = 43). Cyan
areas are regions were hydrophobic interactions are favored whereas those areas shown in
purple are regions where hydrophobic interactions are unfavorable. MD-354 (42) is the
compound displayed in the model.

Results from CoMSIA studies indicated that hydrophobic interactions are favored
near the aryl 3-position, the aryl 5-position, and near the terminal amine in the guanidine
moiety. There was a much larger area of unfavorable hydrophobic interactions, which
was observed near the aryl 4-position as well as in the center of the aromatic ring;
typically, compounds with nonpolar substituents at these positions would be predicted not
to bind well.
From these findings, the binding affinities of five new compounds recently
synthesized in our laboratories, whose binding affinities have not yet been determined,
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were predicted as shown in Figure 65. The binding affinities were predicted using
CoMFA as this model displayed higher predictability than the CoMSIA model.
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Figure 65. Predicted pKi values of five new arylguanidine analogs using CoMFA
analysis.

These predictions will be compared to the actual binding affinities of these
compounds once radioligand binding data become available.
This information further extends the current working pharmacophore model for 5HT3 arylguanidine and arylbiguanide agonists and partial agonists. Evidence from the
current investigation supports the idea that binding is sensitive to electronic and lipophilic
substituents at the aryl 3- and aryl 5-positions as well as lipophilic substituents at the aryl
4-position. Information provided from this model gives insight into what features are
necessary to bind with high affinity to the 5-HT3 receptor. Based on this, design of novel
compounds can be facilitated.
QSAR studies are extremely helpful in designing novel ligands that could bind
with high affinity, by understanding which regions of the receptor prefer which type of
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substituents (i.e., electron-withdrawing versus electron-donating groups). The present
investigation shows that electrostatic factors are preferred in the majority of the model
except at aryl 5- and aryl 6- positions. However, di-substituted ligands, preferably
electron-withdrawing groups at the 3- and 5- positions bind with higher affinity than
mono-substituted ligands. Therefore, design of novel di-substituted ligands should be
considered.
Not only are QSAR studies useful in design of ligands, but very helpful in
predicting the binding affinities of ligands. Even though some of the compounds in
Figure 65 have already been synthesized (i.e., all but 104), binding data have not yet been
obtained. Nevertheless, binding affinities have been predicted and compared to each
other. This information can also help in the design of new ligands, as analysis of what
may increase or decrease binding affinity, such as more electronegative substituents, can
help to determine new analogs to be synthesized without having to wait for binding
studies to be conducted.

V. Conclusions

In locomotor activity assays, the goal was to determine the effect, if any, MD-354
might have on the locomotor effects of different psychomotor stimulants. This could
provide information on whether MD-354 is acting through a 5-HT3 receptor agonist or
antagonist mechanism. Since MD-354 is a 5-HT3 partial agonist, it has the potential to
behave as either an agonist or antagonist. The three 5-HT3 receptor ligands MD-354
(42), the 5-HT3 receptor antagonist ondansetron (19), and the 5-HT3 receptor agonist SR
57227A (28) all produced saline-like effects in locomotor activity assays when
administered alone. Effective doses of the four drugs of abuse tested ((+)amphetamine
(2), (+)methamphetamine (3), DOM (10), and cocaine (1)) were determined and used in
combination with the 5-HT3 receptor ligands. MD-354 (42) neither potentiated nor
antagonized the stimulant effect of either (+)amphetamine (2) or (+)methamphetamine
(3). These results were similar to those observed with (+)amphetamine in combination
with ondansetron (19). They suggest that MD-354 might be acting as an antagonist, or is
devoid of action. These results differed from the combination of (+)amphetamine with
SR 57227A, as the 5-HT3 agonist potentiated the stimulant effect of (+)amphetamine on
the parameters of movement episodes, movement time, movement distance, and margin
distance. Combination of MD-354 (42) with cocaine (1) resulted in the potentiation of
stimulant parameters consistent with results observed with a combination of SR 57227A
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(28) and cocaine. This suggests that MD-354 (42) is working through a 5-HT3 receptor
agonist mechanism. These results could be due to the fact that psychomotor stimulants
display increased locomotion due to increased synaptic dopamine levels, and 5-HT3
receptor agonists can indirectly cause release of dopamine. However (+)amphetamine (2)
and (+)methamphetamine (3) increase dopamine levels through a different mechanism of
action than cocaine (1). This could be the reason MD-354 has different effects between
the

phenylalkylamine

stimulants

versus

the

non-phenylalkylamine

stimulant.

Combination of MD-354 (42) with the phenylalkylamine control non-stimulant DOM
(10) resulted in antagonism of the effect that hallucinogens commonly have on various
parameters. This antagonism versus potentiation, or no effect at all, could be due to the
fact that DOM is not a stimulant and does not work through releasing dopamine.
Various trials were employed to synthesize the more lipophilic phenyl carbamate
analogs of MD-354, which were to be used in animal studies as prodrugs of MD-354.
Lack of stability of the carbamates made isolation of the phenyl carbamate analog of
MD-354, 53, extremely complex. However, by avoiding heat, air, and water the phenyl
carbamate analog of MD-354, 53, could be isolated using bulky alcohols to precipitate
the product. However, upon exposure to heat and water, the phenyl carbamate analog 53
was rapidly hydrolyzed to starting material MD-354 (42). This lack of stability precluded
animal studies from being conducted. Other phenyl carbamate analogs were even more
unstable, and could not be isolated as they decomposed upon standing.
The current working pharmacophore model for arylguanidine and arylbiguanide
5-HT3 receptor agonists and partial agonists was further developed by the addition of
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constrained analogs to the model to help account for rotameric binding that can occur
based on the presence of two meta-substitution positions. This model indicated that the
3- and 5-positions are sensitive to lipophilic and bulky substituents. Information from the
model can be used to design high affinity 5-HT3 receptor ligands. CoMFA studies were
used to predict the binding affinity of several analogs that have been or are being
synthesized in our laboratory, but for which binding data are not yet available. Once
binding data are available, their binding affinities might further validate this model.
In conclusion, the 5-HT3 receptor partial agonist MD-354 may behave as either an
agonist or is devoid of action when administered with psychomotor stimulants that have
different mechanisms of action. It is indicated that this is a central action, although
peripheral action can not be excluded. The effect of MD-354 on DOM locomotor effects
is intriguing and requires further investigation. These effects are very interesting, but
cannot be explained at this time. In regards to synthesis, the more lipophilic carbamate
analogs of MD-354 were unstable preventing use in animal studies as prodrugs of MD354 that could possibly cross the BBB. As such, this is the first study to demonstrate that
phenyl carbamates of guanidines are not stable compounds. QSAR studies were
conducted including conformationally-constrained analogs to help improve the current
working 5-HT3 receptor agonist/partial agonist pharmacophore model for arylguanidines
and arylbiguanides.

VI. Experimental
A. Synthesis
Melting points were taken on a Thomas-Hoover melting point apparatus in glass
capillary tubes and are uncorrected. 1H NMR spectra were recorded with a Varian EM390 spectrometer with tetramethylsilane (TMS) as an internal standard. Peak positions
are given in parts per million (δ). Infared spectra were obtained on a Nicolet Avatar 360
FT-IR spectrophotometer. Microanalyses were performed by Atlantic Microlab Inc.
(Norcross, GA) for the indicated elements and results are within 0.4% of calculated
values. Chromatographic separations were performed on silica gel columns (Silica Gel
62, 60-200 mesh, Sigma-Aldrich). Flash chromatography was performed on a
CombiFlash Companion/TS (Teledyne Isco Inc., Lincoln, NE).

Reactions were

monitored by thin-layer chromatography (tlc) on silica gel GHLF plates (250 μ, 2.5 x 10
cm; Analtech Inc., Newark, DE).

m-Chlorophenylguanidine nitrate (42). m-Chloroaniline HCl (60) (2.36 g, 14.4 mmol),
cyanamide (1.21 g, 28.8 mmol), and absolute EtOH (12 mL) were combined and heated
at reflux overnight. The solvent was removed under reduced pressure and the crude
product was dissolved in H2O (6 mL). Excess NH4NO3 (2.66 g, 33.2 mmol) was added
to form a precipitate that was collected and recrystallized from H2O. The resulting HNO3
salt was collected by filtration, rinsed with anhydrous Et2O (3 x 10 mL), and
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recrystallized a second time from H2O to yield 1.57 g (31%) of product as white crystals
42: mp 170-171 οC (lit.144 mp 171-172 οC). IR (KBr, cm-1) 3420, 3333, 3195, 1659, 1217
cm-1; 1H NMR (DMSO-d6) δ: 7.22 (m, 1H, ArH), 7.33-7.39 (m, 3H, ArH, NH), 7.47 (t,
J=7.8 Hz, 1H, ArH), 7.52 (br.s, 3H, NH), 9.72 (br.s, 1H, HNO3).

Phenyl [[(3-chlorophenyl)amino](imino)methyl]carbamate (53).

Method A.

A

solution of phenyl chloroformate (63) (0.08 mL, 0.63 mmol ) in dry THF (3 mL) was
added in a dropwise manner to a mixture of m-chlorophenylguanidine (42, free base)
(0.11 g, 0.63 mmol) and Et3N (0.18 mL, 1.26 mmol) in dry THF (3.5 mL) on ice under a
N2 atmosphere. The reaction mixture was allowed to stir for 25 min at room temperature,
then filtered twice to ensure all Et3N·HCl was collected. The solvent was evaporated
under reduced pressure. A few drops of isopropanol were added to the resultant crude
product and the solution was placed in the refrigerator for 1 h. The precipitate was
collected by filtration and washed with anhydrous Et2O. The solid was dried under
vacuum for 48 h to yield 0.04 g (19%) of a white crystalline product, 53: mp 159-161 ºC;
IR (KBr, cm-1) 3463, 3288, 3051, 1668;

1

H NMR (DMSO-d6) δ: 7.09-7.27 (m, 6H,

ArH), 7.37-7.42 (t, 2H, ArH), 7.61 (s, 1H, ArH), 9.28 (3H, NH, D2O exchangeable).
Anal. calcd. for C14H12N3O2Cl•0.25Et2O: C, 58.45; H, 4.74; N, 13.63 Found: C, 58.38;
H, 4.42; N, 13.77.

Method B. A solution of phenyl chloroformate (63) (0.38 mL, 3.05 mmol ) in dry THF
(11 mL) was added in a dropwise manner to a mixture of m-chlorophenylguanidine (42,
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free base) (0.52 g, 3.05 mmol) and Et3N (0.85 mL, 6.10 mmol) in dry THF (16 mL) in an
ice bath under a N2 atmosphere. The reaction mixture was allowed to stir for 25 min at
room temperature, then filtered twice to ensure all Et3N·HCl was collected. The solvent
was evaporated under reduced pressure. A few drops of n-butanol were added to the
resultant crude product and the solution was placed in the refrigerator for 1 h. The
precipitate was collected by filtration and rinsed with anhydrous Et2O. The solid was
dried under vacuum for 48 h to yield 0.03 g (3%) of a white crystalline product, 53: mp
159-160 ºC; 1H NMR (DMSO-d6) δ: 7.07-7.29 (m, 6H, ArH), 7.38-7.42 (t, 2H, ArH),
7.62 (s, 1H, ArH), 9.28 (3H, NH, D2O exchangeable).

Method C. A solution of cyanamide (2.5 g, 60 mmol) in H2O (25 mL) was basified with
50% NaOH (pH 7-8). Phenyl chloroformate (63) (9.4 g, 60 mmol) was added in a
dropwise manner and the reaction mixture was allowed to stir at 43 ºC for 1 h. An
unidentified precipitate was collected by filtration; mp >300 ºC. A second product was
determined to be phenol (67) by tlc analysis compared to commercially available phenol;
Rf = 0.83 (3:2 hexane:EtOAc).

2-Amino-7-chloro-3,4-dihyroquinazoline hydrochloride (56).156 BH3-THF complex
(12.2 mL, 1 M, 6.1 mmol) was added in a dropwise manner to 105 (0.6 g, 3.07 mmol)
under a N2 atmosphere. The reaction mixture was heated at reflux for 2.5 h. After cooling
the reaction mixture to room temperature, a 6 N solution of HCl (2.1 mL) was added in a
dropwise manner releasing a gas. Then, a 6 N solution of NaOH (8.4 mL) was added to
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basify the mixture. Upon standing, a white precipitate formed and was removed by
filtration. The solvent was removed under reduced pressure and the residue was dissolved
in hot H2O (20 mL), and extracted with hot CHCl3 (20 mL x 3). The solid at the interface
was collected and dried under reduced pressure for 4 h to give 0.15 g (28%) of a white
solid (56, free base): mp 178-180 °C, 1H NMR (DMSO-d6) δ: 3.45 (br.s., 1H, NH, D2O
exchangeable), 4.30 (s, 2H, CH2), 6.11 (br.s., 1H, NH, D2O exchangeable), 6.60 (s, 1H,
ArH), 6.73 (d, 1H, ArH), 6.89 (d, 1H, ArH).
A solution of 56 (free base) (0.13 g, 0.72 mmol) in EtOH was cooled in an
ice/water bath. Gaseous N2 was bubbled through the solution for 5 min to remove any
moisture followed by bubbling of gaseous HCl for 15 min. The solvent was removed
under reduced pressure to give a white solid. The solid was recrystallized from absolute
EtOH to afford 0.08 g (53%) of a white crystalline solid 56: mp 249-251 °C; IR (KBr,
cm-1): 3300, 3190, 2979, 2927, 2855, 1700, 1618, 1493, 1091; 1H NMR (DMSO-d6) δ:
4.45 (s, 2H, CH2), 7.07 (d, 1H, ArH), 7.17 (dd, 1H, ArH), 7.25 (d, 1H, ArH), 7.77 (s, 2H,
NH2, D2O exchangeable), 8.63 (s, 1H, NH, D2O exchangeable), 11.02 (s, 1H, NH+, D2O
exchangeable). Anal. Calcd. for C8H8N3Cl · HCl · 0.25 H2O: C, 43.17; H, 4.30; N, 18.89
Found: C, 43.41; H, 4.05; N, 18.50.

2-Amino-6-chloro-3,4-dihydroquinazoline

hydrochloride

(57).

The

quinazolinone 74 (0.52 g, 2.65 mmol) was added to 1M BH3-THF (11 mL) and heated at
reflux under N2 gas for 2.5 h. The borate complex was then hydrolyzed by the dropwise
addition of 6 N HCl (2 mL), then basified with 6 N NaOH (8 mL). The mixture was
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concentrated, dissolved in boiling H2O, and extracted with hot CHCl3 (3 x 10 mL).
Solvent was removed under reduced pressure and the resultant solid was rinsed with Et2O
to yield 0.26 g (54%) of white solid 57 (free base): mp 225-230 ºC; IR (KBr, cm-1) 3422,
3102; (DMSO-d6) δ: 4.28 (s, 2H, CH2Ar), 5.63 (br.s, 2H, NH, D2O exchangeable), 6.23
(br.s, 1H, NH, D2O exchangeable), 6.55-6.58 (d, 1H, ArH), 6.91 (s, 1H, ArH), 6.96-6.99
(d, 1H, ArH).
A solution of HCl/Et2O (20 mL) was added in a dropwise manner to a stirred
solution of 57 (free base) in hot EtOH (~10 mL). The reaction mixture was allowed to
stir at room temperature for 10 min. The solvent was evaporated under reduced pressure.
The resultant crude product was recrystallized from hot absolute EtOH to yield 0.06 g
(19%) of off-white crystals 57: mp 237-238 ºC; 1HNMR (DMSO-d6) δ: 4.49 (s, 2H,
CH2Ar), 6.99-7.02 (d, 1H, ArH), 7.30-7.38 (d, 2H, ArH), 7.80 (br.s, 2H, NH, D2O
exchangeable), 8.69 (s, 1H, NH, D2O exchangeable), 11.16 (s, 1H, NH+, D2O
exchangeable). Anal. Calcd. for C8H8N3Cl·1.25HCl·0.25H2O: C, 41.47; H, 4.24; N, 18.13
Found: C, 41.89; H, 3.96; N, 18.05.

Methyl [[(3-chlorophenyl)amino](imino)methyl]carbamate (62). Method A.

A

solution of calcium cyanamide (0.64 g, 8.04 mmol) and H2O (4 mL) was added in a
dropwise manner to methyl chloroformate (61) (0.56 mL, 7.32 mmol) and the reaction
mixture was allowed to stir at 45 ºC for 20 min. The solid was removed by filtration and
then 3-chloroaniline hydrochloride (60) (0.60 g, 3.66 mmol) was added. The reaction
mixture was made slightly more basic (pH 4) by the addition of 40% NaOH and heated at

reflux for 4.5 h.
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The solution was filtered and solvent evaporated under reduced

pressure. The crude product was recrystallized from MeOH to yield 0.07 g (9%) of a
white crystalline solid 62: mp 132-134 ºC (lit.145 138-140 ºC); tlc similar to that of
previously synthesized sample12 Rf = 0.83 (9:1 CH2Cl2:MeOH); IR (KBr, cm-1) 3443,
3350, 1741, 1669; 1H NMR (DMSO-d6) δ: 3.6 (s, 3H, OCH3), 7.11-7.15 (d, 1H, ArH),
7.24-7.36 (m, 2H, ArH),7.48 (3H, NH, D2O exchangeable) 7.69 (s, 1H, ArH).

Method B. A solution of phenyl chloroformate (63) (0.34 mL, 2.70 mmol) in dry THF
(10 mL) was added in a dropwise manner to a mixture of m-chlorophenylguanidine (42,
free base) (0.46 g, 2.70 mmol) and Et3N (0.75 mL, 5.41 mmol) in dry THF (15 mL) in an
ice bath under a N2 atmosphere. The reaction mixture was allowed to stir for 15 min at
room temperature, then filtered. The solvent was evaporated under reduced pressure to
yield a yellow oil. Flash chromatography (3:2 hexane:EtOAc) was conducted to separate
the products. The isolated crude product was recrystallized from acetone to yield 0.02 g
(3%) of a white solid: mp 129-132 ºC (lit.135 128-129 ºC); 1H NMR (DMSO-d6) δ: 3.55
(s, 3H, OCH3), 7.05-7.09 (d, 1H, ArH), 7.26-7.31 (m, 2H, ArH), 7.59 (s, 2H, NH, D2O
exchangeable) 7.78 (s, 1H, ArH), 9.19 (s, 1H, NH, D2O exchangeable). Anal. Calcd. for
C9H10N3O2Cl · 0.25 acetone: C, 48.35; H, 4.79; N, 17.35 Found: C, 48.63; H, 4.61; N,
17.94.

Method C. A solution of phenyl chloroformate (63) (0.45 mL, 3.55 mmol) in dry THF
(13 mL) was added in a dropwise manner to a mixture of m-chlorophenylguanidine (42,
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free base) (0.60 g, 3.55 mmol) and Et3N (9.90 mL, 7.10 mmol) in dry THF (20 mL) in an
ice bath under a N2 atmosphere. The reaction mixture was allowed to stir overnight (17
h) at room temperature then filtered. The solvent was evaporated under reduced pressure
to give a yellow oil. A solid precipitated upon the addition of hot MeOH and was
recrystallized from MeOH to yield 0.13 g (17%) of a white crystalline solid 62: mp 136138 ºC (lit.145 138-140 ºC); 1H NMR (DMSO-d6) δ: 3.48 (s, 3H, OCH3), 7.02-7.13 (d, 1H,
ArH), 7.25-7.36 (m, 2H, ArH), 7.53 (s, 2H, NH, D2O exchangeable), 7.78 (s, 1H, ArH),
9.15 (s, 1H, NH, D2O exchangeable).

N,N’-bis(3-chlorophenyl)urea (64). Method A. A solution of calcium cyanamide (0.54
g, 7.74 mmol) and H2O (2 mL) was added in a dropwise manner to phenyl chloroformate
(63) (0.77 mL, 6.02 mmol). The reaction mixture was allowed to stir at 45 ºC for 20 min.
The solid was removed by filtration and 3-chloroaniline hydrochloride (60) (0.50 g, 3.05
mmol) was added to the solution. The mixture was made slightly more basic (pH 4) by
the addition of 40% NaOH and heated at reflux overnight. The solution was filtered and
solvent evaporated under reduced pressure. The crude product was recrystallized from
MeOH to yield 0.07 g (8%) of white crystalline solid 64: mp 246-248 ºC (lit.146 245 ºC);
1

H NMR (DMSO-d6) δ: 7.04-7.07 (dd, 2H, ArH), 7.30-7.33 (m, 4H, ArH), 7.73 (s, 2H,

ArH), 8.99 (s, 2H, NH, D2O exchangeable).

Method B. A solution of calcium cyanamide (0.64 g, 8.04 mmol) and H2O (2 mL) was
added in a dropwise manner to 4-chlorophenyl chloroformate (65) (1.02 mL, 7.32 mmol).
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The reaction mixture was allowed to stir at 45 ºC for 30 min. The solid was removed by
filtration and 3-chloroaniline hydrochloride (60) (0.60 g, 3.66 mmol) was added to the
solution. The mixture was made slightly more basic (pH 4) by the addition of 40%
NaOH and was heated at reflux overnight.

The solution was filtered and solvent

evaporated under reduced pressure. The crude product was recrystallized from MeOH to
yield 0.03 g (3%) of white crystalline solid 64: mp 241-243 ºC (lit.146 245 ºC); 1H NMR
(DMSO-d6) δ: 7.04-7.07 (dd, 2H, ArH), 7.30-7.33 (m, 4H, ArH), 7.73 (s, 2H, ArH), 8.99
(s, 2H, NH, D2O exchangeable).

Method C. A solution of calcium cyanamide (0.54 g, 6.70 mmol) and H2O (2 mL) was
added in a dropwise manner to 4-methoxyphenyl chloroforomate (66) (0.91 mL, 6.10
mmol). The reaction mixture was allowed to stir at 45 ºC for 30 min. The solid was
removed by filtration and 3-chloroaniline hydrochloride (60) (0.50 g, 3.05 mmol) was
added to the solution. The mixture was made slightly more basic (pH 4) by the addition
of 40% NaOH and heated at reflux overnight. The solution was filtered and solvent
evaporated under reduced pressure. The crude product was recrystallized from MeOH to
yield 0.05 g (6%) of a white crystalline solid 64: mp 239-240 ºC (lit.146 245 ºC); 1H NMR
(DMSO-d6) δ: 7.04-7.07 (dd, 2H, ArH), 7.30-7.33 (m, 4H, ArH), 7.72 (s, 2H, ArH), 8.98
(s, 2H, NH, D2O exchangeable).

Method D. A solution of phenyl chloroformate (63) (0.43 mL, 3.41 mmol) and CH2Cl2
(1 mL) was added in a dropwise manner to a solution of 1H-pyrazole-1-carboxamide
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hydrochloride (69) (0.50 g, 3.41 mmol), DIEA (1 mL), and CH2Cl2 (3 mL). The reaction
mixture was allowed to stir at room temperature for 2 h, then extracted using NaHCO3
and brine; the extract was dried for 1 h with Na2SO4. The solvent was evaporated under
reduced pressure to yield 0.53 g (68%) of a white solid, 70: mp 101-105 ºC.

1

H NMR

(DMSO-d6) δ: 6.63 (s, 1H, ArH), 7.19-7.28 (m, 4H, ArH), 7.41-7.46 (t, 1H, ArH), 7.97
(s, 1H, ArH), 8.46-8.47 (d, 1H, ArH), 8.90 (s, 1H, NH, D2O exchangeable), 9.25 (s, 1H,
NH, D2O exchangeable). Anal. Calcd for C11H10N4O2: C, 57.39; H, 4.38; N, 24.34
Found: C, 55.56; H, 4.22; N, 23.46.
The pyrazole ester (70) (0.35 g, 1.52 mmol) was added to a mixture of mchloroaniline hydrochloride (60) (0.75 g, 4.56 mmol) and DIEA (0.9 mL). The reaction
mixture was heated at reflux overnight. The solvent was evaporated under reduced
pressure to yield a brown oil. The product was isolated using column chromatography
(3:2 hexane:EtOAc) and recrystallized from acetone to yield 0.10 g (23 %) of a white
solid, 64: mp 244-246 ºC (lit.146 245 ºC); 1H NMR (DMSO-d6) δ: 7.04-7.06 (d, 2H, ArH),
7.27-7.35 (t, 4H, ArH), 7.71 (s, 2H, ArH), 9.01 (s, 2H, NH, D2O exchangeable). Anal.
Calcd for C13H10N2OCl2: C, 55.54; H, 3.59; N, 9.96 Found: C, 55.51; H, 3.47; N, 9.82.

N,N,N’,N’-Tetrakis(phenylcarbamate)-3-chlorphenylguanidine hydrochloride (68).
A solution of calcium cyanamide (1.07 g, 13.4 mmol) and acetone (15 mL) was added in
a dropwise manner to phenyl chloroformate (63) (1.53 mL, 12.2 mmol) and allowed to
stir at room temperature under an N2 atmosphere for 20 min. The solid was removed by
filtration and 3-chloroaniline hydrochloride (60) (1.00 g, 6.10 mmol) was added to the
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solution; stirring was allowed to continue for another 5 h. The solution was filtered and
solvent evaporated under reduced pressure. The crude product was recrystallized from
acetone to yield 0.19 g (5%) of a white solid 68: mp 84-87 ºC; IR (KBr, cm-1) 3257,
1710, 1586; 1H NMR (DMSO-d6) δ: 7.11-7.14 (d, 2H, ArH), 7.24-7.48 (m, 20H, ArH),
7.64 (s, 2H, ArH), 10.50 (s, 1H, NH+). Anal. Cald. For C35H24N3O8Cl · HCl: C, 59.83; H,
3.80; N, 6.34 Found: C, 61.25; H, 4.02; N, 6.0.

2-Amino-6-chloro-4-dihydroquinazolinone (74). S-Methylisothiouronium sulfate (72)
(2.04 g, 7.31 mmol) and Na2CO3 (1.19 g, 11.24 mmol) were added to dry 1,4-dioxane (34
mL). The suspension was heated until all of the isothiourea was dissolved. 5Chloroisatoic anhydride (73) (2.00 g, 10.12 mmol) was added, and the reaction mixture
was heated at reflux for 21.5 h. The reaction mixture was allowed to cool to room
temperature and poured into 15 mL of H2O. The mixture was allowed to stir for 20 min
at room temperature. The solid paste 74 was collected by suction filtration and dried
under vacuum at 60 ºC for 24 h to yield 1.02 g (71%) of yellow solid 74: mp>300 ºC; tlc
similar to that of previously synthesized product13 Rf = 0.26 (H2O); IR (KBr, cm-1) 3412,
3174, 3081, 1679; 1H NMR (DMSO-d6) δ: 6.56 (br.s, 2H, NH, D2O exchangeable), 7.207.23 (d, 1H, ArH), 7.56-7.60 (d, 1H, ArH), 7.80 (s, 1H, ArH), 11.22 (br.s, 1H, NH, D2O
exchangeable). The product was used in the synthesis of 57.

m-Fluorophenylguanidine nitrate (101).156 A mixture of m-fluoroaniline hydrochloride
(1.00 g, 6.78 mmol) and cyanamide (0.38 g, 9.04 mmol) was heated at reflux in absolute

168
EtOH (5 mL) for 6 h. The solvent was removed under reduced pressure to give a pale
yellow oil which was dissolved in H2O (2 mL), and NH4NO3 (1.00 g, 12.5 mmol) was
added in excess. The solvent was removed under reduced pressure and the residue was
recrystallized (H2O x 4). The light brown crystals were collected by filtration and washed
with cold Et2O (3 x 5mL) to give 0.81 g (55 %) of a solid product, 101: mp 145-146 °C
(H2O), 146-147 °C (EtOH) (lit.157 165 °C EtOH); IR (KBr, cm-1): 3342, 3330, 3195,
1669, 1597, 1493, 1369, 1143; 1H NMR (DMSO-d6) δ: 7.21-7.04 (m, 3H, ArH), 7.537.45 (m, 5H, ArH, NH2, ex with D2O), 9.72 (s, 1H, NH, D2O exchangeable). Anal. calcd
for C7H8FN3 · HNO3: C, 38.89; H, 4.20; N, 25.92 Found: C, 39.08; H, 4.15; N, 25.89.

m-Iodophenylguanidine nitrate (102).158 m-Iodoaniline hydrochloride (4.4 g, 17.22
mmol) and cyanamide (2.1g, 50.0 mmol) were added to absolute EtOH (20 mL). The
reaction mixture was heated at reflux for 24 h and cooled to room temperature. Distilled
water (5.0 mL) was added to the solution followed by addition of NH4NO3 (10.0 mL). A
white precipitate was promptly formed and recrystallized from distilled H2O. The product
was further purified by flash chromatography (9:1 CH2Cl2:MeOH) to afford white
crystals 0.40 g (7%) 102: mp 166–168 ºC; ¹H NMR (DMSO-d6) δ: 7.25 (t, J = 8.40 Hz,
1H, ArH), 7.27-7.30 (m, 1H, ArH), 7.49 (br s, 5H, NH2, D2O exchangeable), 7.62-7.63
(m, 1H, ArH), 7.65-7.69 (m, 1H, ArH). Anal. Calcd for C7H8N3I · HNO3: C, 25.94; H,
2.80; N, 17.29 Found: C, 25.73; H, 2.72; N, 16.98.
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m-Bromophenylguanidine nitrate (103).
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3-Bromoaniline hydrochloride (4.0 g, 19.2

mmol) and cyanamide (2.1g, 50.0 mmol) were added to absolute EtOH (20 mL). The
reaction mixture was heated at reflux for 24 h and cooled to room temperature. Distilled
water (5.0 mL) was added to the solution followed by addition of NH4NO3 (10.0 mL). A
white precipitate was promptly formed and recrystallized from distilled H2O. The product
was further purified by flash chromatography (9:1 CH2Cl2:MeOH ) to afford white
crystals 0.72 g (14%) 103: mp 160–162 ºC; ¹H NMR (DMSO-d6) δ: 7.26 (ddd, J = 7.80
Hz, 1H, ArH), 7.41 (t, J = 7.80 Hz, 1H, ArH), 7.47-7.52 (m, 7H, ArH and NH2, D2O
exchangeable). Anal. Calcd for C7H8N3Br · HNO3: C, 30.34; H, 3.27; N, 20.22 Found: C,
30.14; H, 3.16; N, 19.95.

2-Amino-7-chloro-4-dihydroquinazolinone (105).156 4-Chloroisatoic anhydride (1.00
g, 5.06 mmol) was dissolved in acetonitrile (24 mL, 80%), then S-methylthioisourea
sulfate (72) (1.4 g, 5.06 mmol) and Na2CO3 (0.58 g, 5.47 mmol) were added to the
solution. The resulting solution was heated at reflux for 5 h. The reaction mixture was
allowed to cool to room temperature over 0.5 h. The suspension was filtered and washed
with acetonitrile (80%, 25 mL x 3). The solvent was evaporated under reduced pressure
then dissolved in CH2Cl2 (10 mL) and extracted with H2O (10 mL x 3). The layers were
separated and the organic layer was dried over MgSO4, filtered, and the solvent removed
under reduced pressure. The residue was purified by column chromatography (9:1:0.1,
CH2Cl2:MeOH:NH4OH). The reaction gave 0.64 g (65%) of a pale pink solid 105: mp
>300 °C (lit.159 >300 °C); IR (KBr, cm-1): 3401, 3133, 1597, 1442, 1101; 1H NMR
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(DMSO-d6) δ: 6.58 (br.s., 2H, NH2, D2O exchangeable), 7.11 (dd, 1H, ArH), 7.21 (d, 1H,
ArH), 7.87 (d, 1H, ArH), 11.10 (br.s., 1H, NH, D2O exchangeable). The product was
used in the synthesis of 56.

B. Behavioral Studies
1. Animals
Male ICR mice (19-29 g) were used throughout the study (Harlan Laboratories;
Indianapolis, IN). Mice were housed in groups of 5-6, with free access to food and water
in a temperature-controlled environment under a standard 12:12 h dark/light cycle in an
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)approved facility. The experiments were conducted in accordance to standards set by the
Institutional Animal Care and Use Committee (IACUC) of Virginia Commonwealth
University. Mice were allowed to adapt to the testing environment at least 1 h prior to
any treatment, and weighed the same day as the experiments.

2. Drugs
(+)Amphetamine sulfate and cocaine hydrochloride (Lot 11K1085J) were
purchased from Sigma-Aldrich Chemical Company (Milwaukee, WI).

(±)1-(2,5-

Dimethoxy-4-methylphenyl)-2-aminopropane (DOM) hydrochloride was obtained from
the National Institute on Drug Abuse (NIDA; Rockville, MD). (+)Methamphetamine
hydrochloride was a gift from Dr. R. A. Glennon (Virginia Commonwealth University).
SR 57227A (4-amino-(6-chloro-2-pyridyl)-1piperidine) hydrochloride was purchased
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from Tocris (Batch 1A/45893; Ballwin, MO). Ondansetron hydrochloride (Zofran , Lot
®

CO99723; GlaxoSmithKline) was purchased from MCVH-Pharmacy. Solutions were
prepared fresh daily; all drugs were dissolved in 0.9% saline and administered to mice in
a total volume of 10 ml/kg body weight by intraperitoneal (i.p.) injections.

3. Locomotor Activity Assays
Mice, naïve to the test apparatus, were placed in individual Tru-Scan Activity
System (Coulbourn Instruments, Allentown, PA) photocell activity cages (40 cm3). Tests
were conducted between 0800 h and 1730 h. The mice were treated with either saline (0min pre-injection time), MD-354 (1.0, 3.0, 6.0, or 10 mg/kg; 0-min pre-injection time or
30-min pre-injection time), ondansetron (0.1, 0.5, or 1.0 mg/kg; 30-min pre-injection
time), SR 57227A (1.0, 3.0, or 10 mg/kg; 30-min pre-injection time), alone or in
combination with (+)amphetamine (2.0 or 3.0 mg/kg; 0-min pre-injection time),
(+)methamphetamine (1.5 or 3.0; 0-min-preinjection time), cocaine (10 mg/kg; 0-min
pre-injection time) and DOM (0.3 mg/kg; 0-min pre-injection time). Other mice were
treated with (+)amphetamine (0.3, 1.0, 3.0, or 6.0 mg/kg; 0-min pre-injection time),
(+)methamphetamine (0.3, 1.0, 1.5, 3.0, or 10 mg/kg; 0-min pre-injection time), cocaine
(1.0, 3.0, 10, or 30 mg/kg; 0-min pre-injection time) or DOM (0.3, 1.0, or 3.0 mg/kg; 0min pre-injection time). The mice were only tested once and each dose of test agent (or
combination of drugs) was studied in 6-8 mice (n = 6-8 mice/treatment). The behavioral
analysis examined nine measures of activity: movement episodes, movement time (s),
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movement distance (cm), vertical entries, margin distance (cm), margin time (s), center
distance (cm), center time (s), and center entries.

4. Statistical Analysis
Data for each measure of activity were analyzed statistically by a one-way
analysis of variance (ANOVA) followed by a Newman-Keuls post-hoc comparison test.
t-Tests were also employed in some analysis instead of a one-way ANOVA, when data
suggested a statistical significance which was not supported by a one-way ANOVA or
post-hoc comparison.

C. Molecular Modeling
The computational studies were performed on a Silicon Graphics workstation
using SYBYL (SYBYL Molecular Modeling Package, Version 7.3, 2007; Tripos Inc., St.
Louis, MO) software.
program.

Compound 42 was built using an arginine fragment in the

Compound 30 was built from its crystal structure downloaded from the

Cambridge Database. All of the compounds we constructed using standard bond lengths
and angles within the Build/Sketch command followed by minimization (MINIMIZE)
and calculation of charges by the Gasteiger-Hückel algorithm. The compounds were
individually superimposed using FIT ATOM on templates 42 and 31 to perform a least
squares fit. The linearly independent points (aryl 3-position, aryl 5-position, and the
carbon atom in the guanidine moiety) were used in FIT ATOM. CoMFA and CoMSIA
studies were conducted.
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